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Summary 
Stat3 is an important transcription factor involved in various biological functions. We 
started our research by a cell line based screening of Stat3 regulated epigenetic 
factors and identified a novel target of Stat3: methyltransferase like protein 8 (Mettl8). 
Human Mettl8 is a potential methyltransferase with several featured domains: SANT 
domain, SAM binding domain for methyltransferase activity, nuclear localization 
signal, NRB domain and pS/TQ motif, which is a signature of ATM/ATR substrate. 
Mouse Mettl8 has same domains except pS/TQ motif. Most of our study focused on 
human Mettl8. 
Firstly, we confirmed mouse Mettl8 as a Stat3 target gene by qPCR, ChIP assay, and 
promoter activity assay, human Mettl8 by ChIP assay. 
Secondly, we showed the peculiar localization of overexpressed wildtype and ΔSAM 
Mettl8 protein in human cells by both biochemical cell fractionation and 
immunostaining. 
Then we validated the SAM binding activity of Mettl8 protein in SAM binding assay 
in vitro. We confirmed that Mettl8 can be specifically phosphorylated by ATM kinase 
at Serine 405 pSQ motif. Interestingly Mettl8 modulates the activation of ATM itself 
and its downstream targets such as early DNA damage marker H2AX, cell cycle 
checkpoint kinase Chk2, and p53 tumor suppressor in a manner dependent on the 
SAM binding ability of Mettl8. Triggered by microarray analysis, we found that an 
 VII 
increase of ATM protein level in the ΔSAM Mettl8 mutant cells could be one of the 
reasons underneath. As a result G2/M checkpoint was activated. 
Similar results of ATM pathway activation were observed only with shRNA 
knockdown of both Mettl8 and its close member Mettl2 in the cells, but not by single 
knockdown of Mettl8 or Mettl2. Using the new CRISPR/Cas9 technique, we 
successfully generated cell lines with Mettl8 knocked out, and showed that knocking 
out Mettl8 alone can induce the ATM pathway activation in a similar manner to that 
of ΔSAM mutant Mettl8 or double knockdown. Consistently, an increase of ATM 
protein level was observed in these circumstances. So far the underlining mechanisms 
of ATM expression level change are unknown; our preliminary data suggested ATM 
transcription regulation was not the main reason. Despite the similar changes of ATM 
level and activity, the outcome of cell growth differed significantly between ΔSAM 
mutant Mettl8, double knockdown and Mettl8 KO cells, implicating more broader 
and intricate involvement of Mettl8 in other pathways besides ATM.  
Taken together, our study revealed a new target of Stat3, a new substrate of ATM and 
a novel mechanism regulating ATM expression and ATM activation in DNA damage 
response. Given the essential role of ATM kinase in guarding DNA integrity and in 
other aspects of cellular life, such as neurogenesis and cancer, this Mettl8-ATM 
connection could be an attractive therapeutic target in the long term and worth further 
studies. 
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Chapter 1 Introduction 
1.1 STAT proteins 
Our lab has studied STAT (Signal Transducer and Activator of Transcription) proteins, 
especially Stat3 in different systems for a long time. Stat3 is a well-known 
transcription factor participating in a wide variety of physiological processes such as 
ES cell pluripotency maintenance, embryogenesis, cancer and immunity (Levy & 
Darnell, 2002; Takeda et al., 1997; Ying, Nichols, Chambers, & Smith, 2003; Yu, 
Pardoll, & Jove, 2009). 
STAT proteins are activated by JAK family of receptor-associated tyrosine kinases, 
which are rapidly activated by autophosphorylation triggered by ligand-induced 
receptor dimerization. Activated JAK sequentially phosphorylates the receptor to 
which it has bound, which enables STAT docking to this complex via binding of 
STAT Src-homology-2 (SH2) domain to the phosphotyrosine residue of the receptor. 
This leads to phosphorylation of STAT and triggers its release and dimerization. 
Dimerized phosphorylated STAT proteins rapidly translocate to nucleus and bind to 
certain gene promoters with specific STAT binding sequences (Figure 1) (Levy & 
Darnell, 2002). Both cell-type specific transcription and stereotypic mRNA profiles 
can be induced by STAT signaling in a cell type or tissue specific manner. (Murray, 
2007; H. Wang, Chen, He, Zhou, & Luo, 2013), depending on the genomic 
accessibility of target genes, such as histone modifications or DNA methylations 
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(Alvarez & Frank, 2004), and possibly on cofactors that further refine gene 
expression profiles (Murray, 2007). 
Stat3 can be activated by a plethora of cytokines, growth factors and peptides. 
Interleukin-6 family is one of them (Heinrich, Behrmann, Müller-Newen, Schaper, & 
Graeve, 1998). Oncostatin M (OSM), a member of IL-6 family, is a potent activator 
of Stat3 and is crucial in hepatic maturation (Kamiya, Kinoshita, & Miyajima, 2001). 
Besides transcription factors and signal transduction pathways, the chromatin 
packaging of the genome is also crucial in setting and maintaining the gene 
expression pattern of a cell. We are especially interested in the interplay between 
epigenetics and transcription factors, which in our case is Stat3. Although there are 
reports about epigenetic genes regulated by Stat3, for example, Stat3 as a major 
inducer of DNA (cytosine-5-)-methyltransferase 1 (Dnmt1) transcription in malignant 
T lymphocytes (Q. Zhang et al., 2006), and transcriptional regulation of the histone 
H3 Lys 27 (H3K27) demethylase Jmjd3 by Stat1 and Stat3 as a novel mechanism for 
inflammatory gene expression in microglia (Przanowski et al., 2013), it remains 
largely unappreciated for Stat3 mediated epigenetic regulations. 
To explore Stat3 regulated epigenetics, we screened for Stat3 targets from a large 
number of epigenetics related genes in mouse adult hepatocytes-derived cell lines by 
qPCR (primers available upon request) and found several candidates, one of which is 
methyltransferase like protein 8 (Mettl8), which has a predicted Stat3 binding site.
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Figure 1. Canonical JAK–STAT pathway.  
Sequential tyrosine phosphorylation triggered by cytokine-receptor interaction. Receptor 
dimerization allows transphosphorylation and activation of Janus Kinase (JAKs). This is 
followed by phosphorylation of receptor tails and the recruitment of STAT proteins through 
their SH2 domains. STAT tyrosine phosphorylation then occurs. Dimerization of activated 
(tyrosine phosphorylated) STAT is followed by nuclear entry and expression of target genes. 
Figure and caption adapted from (Levy & Darnell, 2002). 
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1.2 Methyltransferase like protein 8 
1.2.1 Mettl8 gene and protein 
Mettl8 was first reported by Schuger group as TIP (tension-induced/inhibited proteins) 
gene, as splicing isoforms of Mettl8 in mouse were identified in tension induction 
assay (Jakkaraju, Zhe, Pan, Choudhury, & Schuger, 2005). Two different TIPs were 
shown to play divergent roles in myogenic versus adipogenic differentiation of lung 
embryonic mesenchymal cells. Later they claimed that TIP family composed of eight 
isoforms generated by alternative splicing from a single gene (Mettl8) located in 
chromosome 2q22-23 in mouse and 2q31.1 in human (Badri, Zhou, Dhru, Aramgam, 
& Schuger, 2008), although some of these transcripts are regarded as 
nonsense-mediated decay in Ensembl database. According to NCBI, mouse Mettl8 is 
a gene with 10 exons across 118kbp genome and human Mettl8 with 10 exons across 
153kbp. The full-length mRNA of mouse and human Mettl8 are of 2370 bp and 8154 
bp respectively.  
Regulatory transcription factor binding site analysis on mouse Mettl8 gene promoter 
showed that it has binding sites of many important transcription factors, such as Stat3, 
Oct1 (octamer-binding transcription factor-1, also called Pou2F1), AP-1 (activator 
protein 1), and Foxa2 (forkhead box protein A2), all of which are also present in 
human Mettl8 promoter. 
Domains of mouse Mettl8 gene were mapped: a SANT (switching-defective protein 3 
[Swi3], adaptor 2 [Ada2], nuclear receptor corepressor [N-CoR], and transcription 
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factor IIIB [TFIIIB]) domain, a SAM domain (the D/ExGxGxGx signature motif 
present in some S-adenosyl-L-methionine-binding proteins), and an NRB domain 
(nuclear receptor box, represented by the LXXLL signature motif). A nuclear 
localization signal (NLS) was also found in moue Mettl8 with the peptide sequence 
LRFKKGRCL (Badri et al., 2008; Jakkaraju et al., 2005). The corresponding NLS in 
human is LRFKKGHCL with one amino acid difference. 
The Schuger group made an in-depth study of the Mettl8 SANT domain in mouse and 
found that even the shortest isoform of Mettl8 with only SANT domain could induce 
adipogenesis via SANT domain dependent p300 recruitment which in turn showed 
histone acetylation activity on the promoter of PPARγ2, a key adipogenic 
transcription factor (Badri et al., 2008). Yet they failed to detect the SAM binding 
ability of TIP3, one isoform of mouse Mettl8 by filter binding assay (Jakkaraju et al., 
2005). 
So far there were no reports on the physiological role of human Mettl8 protein in 
PubMed. Human Mettl8 was strongly stained in gastric parietal cells, distal renal 
tubules, subsets of lymphoid and bone marrow poietic cells in the Human Protein 
Atlas. In the International Cancer Genome Consortium (ICGC) data portal, 53 
mutations of human Mettl8 gene were found in 40 patient donors in 15 cancer 
projects to date, among which the highest percentage of donor with mutation lies in 
prostate cancer (37.50%), liver cancer (19.05%) and esophageal cancer (13.64%). All 
mutations are single base substitutions located across the gene except only one in 
frame deletion found in ovarian cancer.  
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Full-length human Mettl8 protein has 407 amino acids. Sequence analysis reveals that 
similar to mouse Mettl8, it is featured by an N-terminal SANT domain, a middle 
SAM domain for possible methyltransferase activity, and a C-terminal NRB motif as 
shown in Figure 2. A unique feature of Mettl8 protein is its pS/TQ motif candidate 
that sits at the very C-terminus, suggesting Mettl8 may be a substrate of 
phosphoinositol-3 kinase like kinase (PIKK). Mouse Mettl8 has no pS/TQ motif 
(Figure 3). 
We generated expression vectors with Flag human Mettl8 ΔSANT (52-87aa deleted), 
ΔSAM (200-208aa deleted), and ΔNRB (295-300aa deleted) mutants (Figure 2). To 
study the pS/TQ motif, we mutated Ser405 to either nonphosphorylatable Ala (S405A) 
or phospho-mimic Glu residues (S405E). 




Figure 2. Domain structure of human Mettl8 protein. 
Schematic structure of wildtype human Mettl8 protein. Mettl8 is featured with SANT domain, 
SAM binding domain, NRB domain, NLS and pS/TQ motif, the functions of which are 
described in detail in the main text. The domain structures of Mettl8 mutants used in this study 
are also shown. 
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Figure 3. Sequence alignment of human Mettl8 and mouse Mettl8 proteins.  
Alignment of human Mettl8 with moue Mettl8 protein sequence using Vector NTI software 
showed the lack of pS/TQ motif in mouse Mettl8 protein. 
Identical aa: red text on a yellow background; 
Block of Similar aa: black on a light green background; 
Non-similar aa: black on a white background.
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1.2.2 Methyltransferase 
The most striking feature of Mettl8 is its S-adenosylmethionine (SAM, also known as 
AdoMet) binding domain. SAM was discovered in 1953 as a conjugate of methionine 
and the adenosine moiety of ATP (Catoni, 1953). It is involved in a diversity of 
metabolic reactions and is the second most widely used and versatile small molecule 
ligand after ATP (Loenen, 2006). The most well-known biological role of SAM is as a 
methyl donor for the majority of methyltransferases (MTases) (Figure 4a).  
Most methyl transfer reactions catalyzed by SAM-dependent MTases are bimolecular 
nucleophilic substitution (SN2) reactions, in which one bond is broken and one bond 
is formed synchronously. The methyl groups are transferred from SAM to a large 
variety of acceptor substrates, varying from small molecules to macromolecules like 
protein, nucleic acid, and lipid, generating S-adenosyl-homocysteine (SAH) as the 
by-product (Figure 4A). SAM-dependent MTase are inhibited by the product, SAH, 
which can accumulate in the presence of homocysteine because the equilibrium of the 
SAH hydrolase reaction favors SAH formation (Figure 4B) (Moat & McDowell, 
2002). 
The SAM-dependent MTases share little sequence identity, but incorporate some 
highly conserved structural folds (Martin & McMillan, 2002). There are five known 
families of typical SAM-dependent MTases (Classes I to V) based on their distinct 
structural features (Schubert, Blumenthal, & Cheng, 2003). A further class of radical 
SAM-dependent MTases that methylate a range of substrates at unreactive, 
Chapter 1 Introduction 
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non-nucleophilic carbon and phosphorus centers was recently discovered (Q. Zhang, 





Figure 4. Schematic description of methyl transfer reaction. 
A) The SN2 mechanism common to the SAM-dependent MTases.  
Nucleophilic groups of MTase substrates are represented by _XH. 
Figure and caption adapted from (Struck, Thompson, Wong, & Micklefield, 2012). 
B) Metabolic relationships between SAM, SAH, and homocysteine in mammalian cells. The 
details are described in the main text. The methyl-accepting substrates are designed X. 
Figure and caption adapted from (Moat & McDowell, 2002).
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The SAM binding domain of Mettl8 consists of seven-stranded beta sheet with three 
helices on each side, which defines the Rossmann fold (Figure 5), a hallmark 
structure of class I methyltransferase (Schubert et al., 2003). The N-terminal region of 
this core fold contains highly conserved glycine-rich sequence E/DXGXGXG (often 
referred to as motif I) between the first β-strand (β1) and the α-helix (αA), which 
interacts with the amino acid portion of SAM (Struck et al., 2012). 
Class I MTases with the Rossmann fold are the largest group of MTases, responsible 
for the majority of methylation reactions in all life forms. Through the SN2 
mechanism (Figure 4), they methylate a very large plethora of small molecules, from 
simple halide ions to O-, N-, C-, S-, Se and As-centered nucleophiles in bioactive 
molecules derived from several branches of primary and secondary metabolism 
(Struck et al., 2012). 
 
Figure 5. Rossmann fold. 
Schematic picture of the topology of the core fold of the Class I SAM-MTases, indicating the 
SAM- and substrate-binding regions of the fold. Helices are shown as yellow cylinders, 
strands as red arrows. αC is shown in grey, because it is not always conserved in the core fold. 
The N and C termini are labeled. 
Figure and caption adapted from (Martin & McMillan, 2002). 
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Besides small molecule methylation, the class I MTases also includes all DNA 
methyltransferases (Dnmts) (Struck et al., 2012). DNA methylation is essentially 
involved in a variety of important biological functions including gene expression 
regulation, mutation repair, gene imprinting, preservation of chromosomal integrity, 
X-chromosome inactivation, embryo development and diseases. Based on their 
structure and functions, Dnmts are divided into two major families in mammals: 
maintenance methyltransferase (Dnmt1) and de novo methyltransferases (Dnmt3a, 
Dnmt3b, and Dnmt3L) (Bird, 2002). 
The flexibility of the Class I structure is further illustrated by existence of a large 
family of RNA C5-cytosine MTases within this class (Reid, Greene, & Santi, 1999). 
Some protein methyltransferases (PMTs) also belong to class I MTases. But the 
largest group of PMTs, which are the SET-domain protein methyltransferases, belong 
to the class V MTases. All known SET-domain MTases transfer work on lysine 
residues within various nuclear proteins involved in chromatin function and 
transcription regulation, and also in some diverse proteins like Rubisco and 
cytochrome C (Kozbial & Mushegian, 2005). 
Due to the high diversity of substrates for SAM dependent MTase, it is quite 
challenging to identify the native substrate for a novel MTase (Martin & McMillan, 
2002; T. Petrossian & Clarke, 2009). In a recent bioinformatics study (Richon et al., 
2011), Mettl8 and its close member mettl2 (Figure 6) are clustered closely with 
protein arginine methyltransferase (PRMT) family based on the similarity of SAM 
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binding domain only.  
Mettl2, the closest member of Mettl8 as mentioned, has one variant in mouse and two 
variants in human. Human Mettl2A and Mettl2B are both 378 amino acids with only 
5 amino acids different between each other. Mettl2A is encoded by a gene that maps 
to human chromosome 17q23.2; Mettl2B is encoded by a gene that maps to human 
chromosome 7q32.1. The two human Mettl2 genes might result from gene 
duplication which was a possible evolutionary event. Human Mettl2 has similar 
SANT, SAM, NRB domains and NLS motif to Mettl8, except the S/TQ motif (Figure 
6). 
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Figure 6. Sequence alignment of human Mettl8 and Mettl2A proteins.  
Alignment of human Mettl8 with Mettl2A protein sequence using Vector NTI software 
showed the high homology between these two proteins. 
Identical aa: red text on a yellow background; 
Block of Similar aa: black on a light green background; 
Non-similar aa: black on a white background.
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1.2.3 Methyltransferase like (Mettl) proteins  
There are more than 30 genes assigned as methyltransferase like protein (Mettl) genes 
by the HUGO Gene Nomenclature Committee (HGNC), such as Mettl1, Mettl2A&B, 
Mettl3, Mettl4, Mettl5 etc., but they do not belong to any specific protein family. 
Functions of some of the Mettl proteins were revealed, Mettl1 as a 
7-methylguanosine-methyltransferase (Alexandrov, Martzen, & Phizicky, 2002), 
Mettl2’s homolog ABP140 as a methyltransferase for 3-methylcytidine at position 32 
of tRNAs in Saccharomyces cerevisiae (Noma et al., 2011), Mettl3 as 
N6-adenosine-methyltransferase (Bokar, Shambaugh, Polayes, Matera, & Rottman, 
1997), Mettl6’s effect in cisplatin sensitivity in lung cancer cells (Huang et al., 2011), 
Mettl10 methylating lysine residues of eukaryotic elongation factor 1A in 
Saccharomyces cerevisiae (Lipson, Webb, & Clarke, 2010), Mettl11A as a histone 
methyltransferase (Richon et al., 2011) and human Mettl14 catalyzing m
6
A RNA 
methylation together with Mettl3 (Liu et al., 2013). However, the majority of Mettl 
proteins remain poorly studied, and Mettl8 is one of them.  
1.2.4 pS/TQ motif 
Besides the SAM binding domain, another distinguished and unique feature of human 
Mettl8 protein is its pS/TQ motif candidate that sits at the very C-terminus. 
ATM and its related PIKK family members ATR and DNA-PKcs preferentially 
phosphorylate their substrates on serine or threonine residues followed by glutamine 
residue, so-called SQ/TQ (or S/TQ) motif. This motif was first screened out by a 
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peptide mutagenesis analysis of p53 protein, an established substrate of ATM in 
response to DNA damage (S. T. Kim, Lim, Canman, & Kastan, 1999). 
S/TQ is a minimal essential requirement for all three kinases. But significant 
differences exist in the co-factor requirements of ATM and ATR compared with 





, DNA ends, and Ku proteins. In addition, hydrophobic 
amino acids and negatively charged amino acids immediately N-terminal to serine or 
threonine are positive determinants and positively charged amino acids in the region 
are negative determinants for substrate phosphorylation (S. T. Kim et al., 1999). 
SQ/TQ cluster domains, termed as SCDs, were found in a large number of ATM/ATR 
substrates. SCDs are now generally considered as another signature domain 
characteristic of DNA-damage-response proteins besides BRCT and FHA domains 
(Traven & Heierhorst, 2005). 
As we can see, the C-terminus of Mettl8 sequence STLLSQD fits with all the 
requirements of being a PIKK substrate, so it could be a novel substrate of ATM or 
ATR or DNA-PKcs. And it naturally infers to us whether Mettl8 is related to DNA 
damage. 
 
Chapter 1 Introduction 
17 
1.3 DNA damage response (DDR) 
Keeping an intact genome from generation to generation is crucial for all life 
forms. Human cells are constantly exposed to DNA damages from endogenous 
and exogenous environments tens of thousands of times every day (Ciccia & 
Elledge, 2010). The endogenous damages can come from cellular metabolic or 
hydrolytic processes, oxidative stresses and aging (Barnes & Lindahl, 2004). 
Exogenous insults to DNA integrity include ultraviolet (UV) light, radiation, and 
DNA-damaging chemicals. 
DNA lesions will affect genome replication and transcription. And if left 
unattended or not repaired correctly, DNA damages will have deleterious effects 
to genome stability, as they may lead to gene mutations, wider genome 
aberrations or chromosome instabilities which will affect normal cellular 
functions and result in diseases such as cancers. Genome instability is one new 
hallmark of cancer which enables more mutations, allowing tumor cells to survive, 
proliferate and disseminate (Hanahan & Weinberg, 2011). 
To maintain genome stability, life has evolved the DNA-damage response (DDR). 
DNA damage response involves multi-cascade events to sense the damage, transduce 
the signal and activate the effectors, either to repair DNA or mount checkpoints on cell 
cycle progression (Zhou & Elledge, 2000). DDR is highly related to a lot of 
cellular processes, such as cell cycle, autophagy and apoptosis (Figure 7) (Jackson 
& Bartek, 2009), and has been increasingly appreciated as guardian of genome 
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stability (Bartek, Bartkova, & Lukas, 2007; Bartkova et al., 2005; Bartkova et al., 
2006). DDR defects will lead to numerous diseases, a complete list of which can be 
found in a review by Ciccia, A. and Elledge (Ciccia & Elledge, 2010). 
Being such a crucial protection mechanism, DDR is present from bacteria to plants to 
humans. Here only DDR in mammals especially humans will be introduced.  
To detect and repair different kinds of DNA lesions, cells have developed six major 
repair pathways: BER (base excision repair) to correct small chemical alterations, 
MMR (mismatch repair) to replace mismatched DNA bases with correct ones, NER 
(nucleotide excision repair) to repair more bulky lesions and intrastrand crosslinks, 
DR (direct repair) for direct reversal of DNA alkylation damage, HR (homologous 
recombination) and NHEJ (non-homologous end joining) pathways for DNA double 
strand break repair (Figure 8) (Postel-Vinay et al., 2012). 
There are also other DNA-repair pathways available to guard genome stability, such 
as Fanconi Anemia/BRCA pathway (Kennedy & D'Andrea, 2005), translesion DNA 
synthesis and single-strand annealing.
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Figure 7. Model for the DDR. 
The presence of a lesion in the DNA, which can lead to replication stalling, is recognized by 
various sensor proteins. These sensors initiate signaling pathways that have an impact on a 
wide variety of cellular processes.  
Figure and caption adapted from (Jackson & Bartek, 2009).
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Figure 8. Main DNA lesions and corresponding DNA damage repair pathways. 
DNA lesions that affect a single strand without significantly disrupting the helical structure are 
generally repaired by base excision repair (BER), whereas DNA damage significantly 
distorting the DNA helix is repaired by nucleotide excision repair (NER). Direct repair (DR) 
copes with small chemical changes affecting a single base, and mismatch repair (MMR) 
repairs mismatches in the pairing of DNA caused by replication errors. Finally, homologous 
recombination (HR) and non-homologous end joining (NHEJ), although distinct pathways, are 
both involved in the repair of DNA double-strand breaks: HR allows ‘error free’ repair of the 
lesion whereas NHEJ is an ‘error prone’ mechanism that repairs DNA but at the cost of 
introducing mutations into the genome (Jalal, Earley, & Turchi, 2011). The selection of HR or 
NHEJ is primarily based on the phase of the cell cycle and the expression, availability and 
activation of DNA-repair proteins (Shrivastav, De Haro, & Nickoloff, 2008). 






Figure and caption adapted from (Postel-Vinay et al., 2012). 
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1.4 Double strand break (DSB) repair signaling and ATM 
Among the various kinds of DNA lesions discussed above (Figure 7), DNA double 
strand break (DSB), which usually arises from ionizing irradiation and 
chemotherapeutic drugs, is the most deleterious form of damage to chromosome 
stability, as it will easily lead to chromosome rearrangement and loss if left unrepaired. 
DNA DSB can also arise from meiotic recombination and immunoglobulin gene 
rearrangements. To eliminate DSB with minimum alteration in nucleotide sequence, 
cell has evolved a whole set of complicated machinery which involves a 
spatiotemporal orchestration of an array of protein factors to sense and repair the 
damage efficiently. 
1.4.1 ATM 
ATM (Ataxia telangiectasia mutated), is a big protein with a high molecular weight of 
about 370 kD. It’s a serine/threonine protein kinase belonging to PIKK superfamily. 
Being an apical kinase in DSB signaling, ATM plays a central role in sensing DNA 
DSB and coordinating the checkpoint responses. It has two close PIKK family 
members: ATR (ATM and Rad3 related) and DNAPKcs (DNA dependent protein 
kinase catalytic subunit), which are believed to play some redundant roles but with 
some specificity in different damage circumstances. 
ATM was first identified as the gene responsible for human autosomal recessive 
disorder ataxia-telangiectasia which is characterized with hypersensitivity to 
irradiation, susceptibility of tumor formation, immunodeficiency, neuronal 
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degeneration, chromosomal instability, and cell cycle abnormalities (Savitsky et al., 
1995). Consistently, ATM-deficient mice show many of the same symptoms found in 
human ataxia-telangiectasia patients and in cells derived from them (Elson et al., 
1996; Kuljis, Xu, Aguila, & Baltimore, 1997; Xu et al., 1996; Xu & Baltimore, 1996). 
Upon irradiation ATM is rapidly activated by dimer dissociation and 
auto-phosphorylation at Serine 1981 (Bakkenist & Kastan, 2003). As a key molecule 
initiating the DSB response, ATM activation mechanism has been intensively 
investigated and some elements have been revealed: Mre11-Rad50-Nbs1 (MRN) 
complex is required for recruitment of ATM to the damage site (Uziel et al., 2003) 
and ATM is acetylated by TIP60 (also known as KAT5) at its C-terminus prior to its 
autophosphorylation (Sun, Jiang, Chen, Fernandes, & Price, 2005; Sun, Xu, Roy, & 
Price, 2007), which is recently found to be dependent on H3K9me3 mark and 
tyrosine phosphorylation of TIP60 by C-Abl (Kaidi & Jackson, 2013). It is accepted 
that ATM activation requires both the modification of protein complex and chromatin 
status around the DNA break site, and there is more to be explored given the intrinsic 
complexity of chromatin structure. 
1.4.2 DSB sensing and repair 
As introduced before, there are two major repair pathways for DNA double strand 
break repair: HR (homologous recombination) and NHEJ (non-homologous end 
joining). Besides general genome maintenance, both of these two pathways are 
utilized in specialized recombination reactions. NHEJ is crucial for complete V(D)J 
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recombination and teleomere maintenance, while HR is important for meiosis and 
interstrand crosslink repair (Ferguson & Alt, 2001). The balance between the two 
DSB repair pathways is dependent on species, cell types and different cell cycle 
phases (Shrivastav et al., 2008).There is a detailed, state-of-the-art review on DSB 
repair pathway choice (Chapman, Taylor, & Boulton, 2012). 
Generally, in radiation induced DSB repair, NHEJ pathway is active in all cell cycle 
phases and can be error-prone as it simply rejoins broken DNA ends with no 
template, while HR is preferentially active in late S/G2 phases of the cell cycle when 
a homologous sister chromosome or chromatid is available for direct base-pairing to 
repair of a DNA DSB without error (Figure 9) (Rothkamm, Krüger, Thompson, & 
Löbrich, 2003). In mitotic cells, DSB induced DDR is not fully activated until cells 
enter G1 phase (Giunta, Belotserkovskaya, & Jackson, 2010). Here a general 
interphase full DSB repair signaling is described. 
Within seconds, if DSBs are detected by the Ku70–Ku80 complexes, DNA-PKcs 
will be recruited to damage sites (Falck, Coates, & Jackson, 2005), which 
promotes NHEJ. The enzymes involved in NHEJ include Ku, DNA-PKcs, Artemis, 
XLF (also called Cernunnos), XRCC4, and DNA ligase IV etc. (Figure 9). Poly 
(ADP-ribose) polymerase 1 (PARP1) competes with Ku protein binding to DSBs to 
promote HR (Hochegger et al., 2006). After initial accumulation of the MRN 
complex to DSBs mediated by PARP1 (Haince et al., 2008), ATM is activated 
followed by phosphorylation of a variant of histone H2A called H2AX at its 
C-terminal pS/TQ site (termed γH2AX) (Rogakou, Pilch, Orr, Ivanova, & Bonner, 
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1998). γH2AX is then deposited around DNA double strand breaks, up to 1 mega-base 
surrounding region (Burma, Chen, Murphy, Kurimasa, & Chen, 2001). This will 
substantially propagate the damaging signal and serves as a beacon to recruit many 
mediators to the site, such as mediator of DNA-damage checkpoint 1 (MDC1) (Stewart, 
Wang, Bignell, Taylor, & Elledge, 2003), Mre11-Rad50-Nbs1 (MRN) complex (Uziel 
et al., 2003), p53-binding protein 1 (53BP1) (B. Wang, Matsuoka, Carpenter, & 
Elledge, 2002), BRCA1 (Cortez, Wang, Qin, & Elledge, 1999), and KRAB-associated 
protein-1 (KAP1) (Goodarzi et al., 2008), all of which are substrates of ATM and form 
foci-like structure colocalized with γH2AX in the nucleus upon IR. This so-called IRIF 
(ionizing radiation induced foci) indicates the assembly of complex involving a large 
number of proteins which provides the platform to execute the DNA repair (Figure 9) 
and cell cycle checkpoint function. Proteins involved subsequently in the DSB repair 
include BRCA1/2, replication protein A (RPA), Bloom syndrome protein (BLM), 
X-Ray repair cross-complementing protein 2/3 (XRCC2/3), MUS81-EME1 
complex, RAD51, RAD52, RAD54 and RAD51-B, C, D (Figure 9). 
Although recently ATM was reported to be dispensable for HR repair of 
enzyme-induced euchromatic DSBs, the essential role of ATM in DSB repair is 
unquestionable as ATM-deficient cells are hypersensitive to DSB, suggesting the 
existence of ATM-dependent alternative repair pathways other than HR for DSB 
repair (Rass, Chandramouly, Zha, Alt, & Xie, 2013). ATM is also crucial in 
facilitating heterochromatin DSBs repair by phosphorylating KAP-1 to make the 
heterochromatin less compacted and more accessible to repair (Goodarzi et al., 2008).  




Figure 9. DNA double strand break sensing and repair pathways. 
Under normoxic conditions, a DNA double-strand break (DSB) is sensed by the MRN 
complex. This leads to activation and recruitment of the ATM and DNA-PKcs kinases and 
phosphorylation of the histone variant H2AX (termed γH2AX, yellow) around the site of the 
break. Subsequently, a number of DNA damage sensing proteins, such as mediator of DNA 
damage checkpoint 1 (MDC1) and p53-binding protein 1 (53BP1), and DNA DSB repair 
proteins involved in HR and NHEJ are recruited within the first 1–6 h of damage recognition 
to repair the DNA DSB. The NHEJ repair pathway can be used within any phase of the cell 
cycle and can be error-prone. The HR pathway is preferentially active in the S and G2 phases 
of the cell cycle when a homologous sister chromosome or chromatid is available for direct 
base-pairing to effect error-free repair of a DNA DSB.  
Abbreviations: PARP, poly (ADP-ribose) polymerase; BLM, Bloom syndrome; EME1, 
essential meiotic endonuclease 1 homolog 1 (S. pombe); RPA, replication protein A. 
Figure and caption adapted from (Bristow & Hill, 2008).
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1.5 ATM substrates 
The short S/TQ motif is found in a plethora of substrates in response to DNA damage. 
Among those diversified substrates of ATM, tumor suppressor p53 is well studied. p53 
is found to be rapidly phosphorylated at Serine 15 pSQ site in response to IR (Banin et 
al., 1998), and stabilized via regulation of MDM2-p53 interaction (Chehab, Malikzay, 
Appel, & Halazonetis, 2000; Hirao et al., 2000; S. Y. Shieh, Ikeda, Taya, & Prives, 
1997). This modification is accompanied by p300/PCAF mediated acetylation at its 
C-terminal stretch (Gu & Roeder, 1997; Ito et al., 2001), which collectively then 
modulates p53 transactivation ability and turns on downstream target genes required 
for cell cycle arrest, apoptosis and many other functions. One well-studied effector of 
p53 is p21 (also called WAF1, CIP1) which can inhibit both the cyclin-dependent G1 
kinases and the G2/M-specific CDC2 kinase and thus activate G1 and G2/M cell cycle 
arrest (Agarwal, Agarwal, Taylor, & Stark, 1995). ATM also phosphorylates the 
checkpoint kinase to further intertwine the complex network via the checkpoint kinase 
1/2 (Chk1/2) mediated phosphorylation on p53 as well as MDM2, and cell cycle 
regulator CDC25 (Di Leonardo, Linke, Clarkin, & Wahl, 1994). 
Given the important function of ATM-p53 in genome stability maintenance (Cao et al., 
2006), the mutations compromising this checkpoint are frequently found in different 
tumors, suggesting this DNA damage response is a barrier against tumorigenesis 
beyond its early stage (Bartkova et al., 2005) and become attractive target for cancer 
therapy, which currently heavily depends on DNA damaging agents (Lord & Ashworth, 
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2012). The efficacy depends on more detailed understanding of the elegant regulation 
in ATM-p53 interplay (Jiang et al., 2009).  
The complex disease phenotypes in both AT patients and ATM-deficient mice suggest 
that ATM kinase has pleiotropic physiological functions beyond DNA damage repair. 
Other ATM substrates were demonstrated to be important for chromatin remodeling 
(Morrison et al., 2007), or gene transcription (Shi et al., 2004; Z. H. Wu, Shi, Tibbetts, 
& Miyamoto, 2006). Many more putative ATM substrates with functions not fully 
elucidated yet are predicted to be involved in various aspects of cell life, such as 
DNA/RNA metabolism, intracellular organization and embryo development (Figure 
10) (Shiloh & Ziv, 2013). Many responses that seem to be dependent on ATM are 
likely to link to unknown substrates of ATM. Therefore, it is important to identify the 
specific substrates of ATM associated with these functions. On the other hand, 
studying new substrates of ATM will provide insights into further elucidation of 
ATM functions. 
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Figure 10. Functional classification of putative ATM substrates. 
1,077 proteins were identified in proteomic screens as putative ATM substrates. Initial 
functional division was made using Gene Ontology annotations, and closely related classes 
were subsequently assembled into the shown groups. Some of the groups partially overlap. 
Figure and caption adapted from (Shiloh & Ziv, 2013).
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1.6 Regulation of ATM expression 
Given the important role of ATM in diverse physiological processes, much effort was 
made to study the mechanisms of ATM activation, mutations of ATM and ATM 
substrates. However, little is known about the regulatory mechanisms of ATM 
expression.  
Although ATM expression is generally stable during cell cycle progress or in 
response to genotoxic stimuli, it was reported that ATM can be regulated in vivo at the 
transcriptional level (Gueven et al., 2006), it is upregulated during the mitogenic 
response in peripheral blood mononuclear cells only in protein level (Fukao et al., 
1999), there is an increased basal levels of ATM in the FA mutant fibroblast cell lines 
(Yamamoto et al., 2008) and ATM could be unregulated in both mRNA and protein 
level upon X-irradiation in lymphoblastoid cell lines only when the ATM genes are 
wild type (Hirai et al., 2001). Insights of ATM regulation could be gained from 
studies done in various systems. 
1.6.1 MicroRNA and ATM expression 
MicroRNAs (miRNAs) are naturally existing, small, non-coding RNA molecules with 
an important regulatory function of gene expression in multicellular organisms 
(Bartel, 2004). miRNAs function through base-pairing with complementary 
sequences within target mRNA molecules, usually resulting in translational repression 
or transcripts degradation of target genes. 
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So far, micro RNAs that were reported to be involved in downregulation of ATM 
include miR-181 in breast cancer (Y. Wang et al., 2011), miR-18a in breast cancer cell 
and tissues (Song, Lin, et al., 2011) (Guo et al., 2013), miR-18a in colorectal cancer 
(C. W. Wu et al., 2013), miR-106a in breast cancer (Guo et al., 2013), miR-421 (Hu, 
Du, Nagabayashi, Seeger, & Gatti, 2010), miR-100 in the human glioma cell line: 
M059J (Ng, Yan, Zhang, Mo, & Wang, 2010), miR-421 in SKX squamous cell 
carcinoma (Mansour et al., 2013), and miR-101 in certain tumors (Yan et al., 2010). 
There is also one contradictory report about miR-18a overexpression leading to 
upregulation of ATM expression in HCT116 cells (Qased et al., 2013). 
1.6.2 Other proteins regulating ATM expression 
It was shown that ATM expression can be regulated by Latent Membrane Protein 1 
(LMP1) via the NF-κB pathways through direct promoter binding in nasopharyngeal 
carcinoma cells (Ma et al., 2011). 
Fusco etc. (Palmieri et al., 2011) reported that High-mobility group A (HMGA) 
proteins 1 and 2, two novel substrates of ATM, are two positive regulators of ATM 
expression and activity by transcriptional activation of ATM promoter, and ATM 
expression is almost totally abolished in HMGA1/2 double knock out MEF cells. 
ATM is transcriptionally regulated by E2F-1, which elevates ATM promoter activity 
and induces an increase in ATM mRNA and protein levels (Berkovich & Ginsberg, 
2003).  
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There are also negative regulators of ATM expression reported, such as tumor protein 
D52 (Y. Chen et al., 2013), protein kinase C (PKC) α in human prostate cancer cells 
in vitro and in vivo (Truman et al., 2009) and sustained stimulation of cells with EGF 
in ATM wild type cells (Keating, Gueven, Watters, Rodemann, & Lavin, 2001). 
More mechanisms that regulate ATM expression and function wait to be discovered.
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1.7 Research aims 
Mettl8 first drew our attention as a potential target of Stat3. It became more 
interesting to us as it has a SAM binding domain which makes it a possible 
methyltransferase, and an S/TQ motif required for ATM substrate, implicating its 
potential role in DDR and tumorigenesis. 
The aim of our research is to elucidate the function of Mettl8, firstly to study its 
localization in cells; secondly to confirm whether it is an active methyltransferase and 
to find its substrate; thirdly to study whether the pSQ motif is indeed phosphorylated 
by ATM in DDR; fourthly to reveal its cellular role in DNA damage response by 
overexpression and knockdown/knockout study; finally to assess its role in cell 
growth, cell transformation and tumorigenesis. 
Chapter 2 Materials and Methods  
33 
Chapter 2 Materials and Methods 
2.1 Antibodies, chemicals and other reagents 
2.1.1 Antibodies 
Antibodies against Stat3 (C-20), p53 (DO-1), p21 (C-10), Hsp90, HA, α-tubulin, actin  
were from Santa Cruz; antibodies against Stat3 pY705, ATM pS1981, Chk2 pT68, 
Phospho-(Ser/Thr) ATM/ATR Substrate, p53 pS15, p53-acetyl K382, Fibrillarin, H2A, 
H2AX, H2AX pS139 were from Cell Signaling; antibodies against ATM, H3 total, 
KAP1, KAP1 pS824, H3K9me3, H3K9Ac and H4K20me2 were from Abcam and 
antibodies against human Mettl8 (HPA035421) and Flag tag (Flag M2) from Sigma. 
2.1.2 Chemicals 
Table 1．List of chemicals used in this study 
Name  Source 
5’FU Calbiochem 





Ku55933 Tocris Biosystem 
Mouse OSM Made in our lab 
Wortmannin Calbiochem 
2.1.3 Other reagents 
Restriction enzymes and T4 DNA ligase are from NEB. 
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2.2 Plasmids 
For recombinant DNA cloning procedures and plasmid DNA amplification, E.coli 
strain DH5α (Invitrogen) was used as host. Bacteria cells were grown in LB liquid or 
solid medium with ampicillin (100μg/ml) for selection of positive cells. Mouse Mettl8 
was cloned from C57BL/6 E13 embryo liver cDNA pool and cloned into pPyCAGIP 
vector (courtesy of Dr. Wu Qiang, NUS) by XhoI/NotI. Human Mettl8 was cloned 
from human lung cancer cell line H2228 and inserted into pPyCAGIP vector by 
XhoI/NotI with Flag tag at N-terminus and HA tag at C-terminus. Point mutation at 
Ser405 and deletion mutation at SANT, SAM, NRB motif were carried out following 
PCR based mutagenesis method (Quikchange). For bacterial expression, human Mettl8 
WT and ΔSAM cDNA were subcloned into pGEX6P1 vector by XhoI/EcoRI. 
pPyCAGIP-Flag-Mettl8-HA was further modified into pPyCAGIP-Flag-Mettl8–HA 
-T2A-EGFP by insertion of T2A peptide gagggcagaggaagtcttctaacatgcggtgacgtggagg- 
agaatcctggccca and EGFP cDNA. All plasmids are verified by sequencing. pLKO.1 
vectors harboring shRNA against Mettl2, Mettl8 and scramble control were 
purchased from Sigma and validated. 
2.3 Cell culture and treatment 
HCT116 (p53 wild type), HEK293T, U2OS and HepG2 cell lines were cultured in 
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal-bovine 
serum (FBS) (Sigma) and antibiotics (100 units/ml penicillin and 100 μg/ml 
streptomycin). H1650 cells were cultured in RPMI-1640 medium with the same 
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supplements as above. The cells were incubated at 37 °C with a humidified atmosphere 
of 5% CO2.  
Gamma irradiation is performed in BioBeam 8000 irradiator (Gamma Service Medical 
GmbH, Leipzig, Germany) with 
137
Cs as radiation source (dosage at 0.048Gy/sec). UV 
radiation is performed in UV Stratalinker 2400. 
2.4 Transfections and viral transduction 
2.4.1 Transfection with Lipofectamine 2000 
The manufacturer’s protocol (Life Technologies) was followed. 
2.4.2 Transfection with calcium phosphate precipitation method 
Transfection was done when cells grow to 30%-40% of confluency. 20 μg of plasmid 
DNA in 450μl autoclaved sterile Milli-Q water was mixed with 50μl of 2.5M 
freshly-made calcium chloride. Then 500μl of 2×BES buffer [50 mM 
N,N-bis(2-hydroxyethyl)-2-aminoethanesulfonic acid (BES), 1.5 mM Na2HPO4, 280 
mM NaCl. Adjust pH to 6.95 with 1 N NaOH] was added and the whole solution was 
vortexed immediately for 1min followed by a 20 min incubation at room temperature 
to allow DNA to precipitate. After incubation, the DNA solution was spun down at 
250g for 30 sec, pipetted up and down several times, and finally added dropwise 
evenly to cells in 10 ml culture media in 10 cm dishes. The transfected cells were 
incubated at 37 °C with 2.5% CO2. After about 16h, media was removed and replaced 
with 10ml fresh media. Then cells were moved back to 37 °C incubator with 5% CO2 
until cells reached full confluency or virus harvest. 
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2.4.3 Viral transduction 
To produce lentiviruses containing shRNA, shRNA-pLKO.1 plasmid or pLKO.1 
control plasmid was transiently transfected in 293T packaging cells with 2nd 
generation packaging plasmid and envelop plasmid for producing viral particles by 
calcium phosphate precipitation method.  
For the viral transduction in cells, Sigma protocol was followed. Briefly, cells to be 
transduced were seeded at appropriate density on Day 0. The next day lentiviruses 
were added to cells in growth media containing polybrene (6-8 μg/ml). Media was 
removed and replaced with fresh growth media on Day 2. After one or two days (cell 
type dependent) to wait for cells to robustly express puromycin resistant gene, media 
was removed and replaced with media containing puromycin, whose concentration is 
cell type dependent. After certain days of puromycin selection (concentration and cell 
type dependent), media containing dead cells was removed and the remaining cell 
population was supposed to contain shRNA of interest. 
The sequences of the shRNAs used are in Table 2. All the shRNA oligos were 
purchased from Sigma.
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Table 2.  List of shRNAs used in this study 
Name Target sequence 
Mettl8 shRNA1 GTTGAGGGAATTTCCTGAAAT 
Mettl8 shRNA2 GCGAGAGAATCATCATGGGAT 
Mettl8 shRNA3 GTGCTACAAATCGTTTCTCAA 
Mettl8 shRNA4 GATCGCCGCTTACAAGTTAAT 
Mettl8 shRNA5 CTCCTTGTGTCTCCGTTTAAA 
Mettl2 shRNA1 GCTAGGCAATTGCAGTTAATA 
Mettl2 shRNA2 CCGAGGAAAGCAACTGACAAT 
Mettl2 shRNA3 CCACAAATACTGGAATGACTT 
Mettl2 shRNA4 CGGGTTTGGATTCAGTGCAAA 
Mettl2 shRNA5 ACCTTAAACCACCATTTATTT 
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2.5 Immunofluorescent staining 
Cells grown on cover slips were washed with PBS solution, fixed in 4% 
paraformaldehyde at room temperature for 20-30 min and permeabilized with 0.2% 
Triton X-100 in PBS for 10 min. Then cells were blocked with 3% BSA in PBS with 
0.1% Triton X-100 for 10 min, followed by incubation with primary antibodies at 4°C 
overnight. Then cells were washed three times with 0.1% Triton X-100 in PBS, each 
time for 10 min and incubated with fluorescence-labeled secondary antibodies in dark 
at room temperature for 1h. Nuclei were visualized by DAPI staining. Coverslips with 
cells were mounted onto slides by VECTASHIELD HardSet Mounting Medium 
(Vector Laboratories, H-1400). 
2.6 Microscopy 
Image acquisition and analysis was performed on Nikon A1R-A1 confocal 
microscopy system. 
2.7 Flow cytometry 
Cells were fixed in ice-cold 70% ethanol at 4℃ overnight. After fixation, the samples 
were washed twice with cold PBS and resuspended in 0.1ml PBS with 50μg/ml 
propidium iodide and 20µg/ml RNAse. After incubation for 45 min at room temperate 
in dark, the samples were diluted by addition of appropriate amount of PBS. The DNA 
content was determined by a BD LSRⅡ flow cytometer. Data was analyzed using 
Flowjo software. 
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2.8 Soft agar colony formation assay 
SeaPlaque™ Agarose with low melting temperature (Lonza, 50100) was used in this 
assay. In triplicate manner, 1.5ml culture medium with 0.6% agarose was first plated 
into each well of a 6-well plate. After base agarose solidified, another 1.5ml of 0.4% 
agarose was plated on top in culture medium containing 2500 cells per well. After 20 
days colonies grown in soft agar were stained by 1mg/ml Thiazolyl Blue Tetrazolium 
Bromide (Sigma, M5655) dissolve in water and then scanned in Bio-Rad Gel Doc EZ 
system. A population with more than 50 cells was counted as one surviving colony. 
Colonies were counted using Quantity One software.  
2.9 Semi-quantitative Real-time PCR 
Total RNA was harvested using Trizol reagent (Invitrogen) according to the 
manufacturer’s instructions, purified by the RNeasy mini kit (Qiagen), and then 
reverse transcribed using the M-MLV Reverse Transcriptase system (Promega). The 
cDNA products were subjected to semi-quantitative RT–PCR with KAPA SYBR® 
FAST Universal 2X qPCR Master Mix (KK4600) using a 7300 Real-Time PCR 
machine (Applied Biosystems). All gene-specific mRNA expression values were 
normalized against the internal housekeeping gene GAPDH. The sequences of primers 
used are in Table 3.
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Table 3．List of primers used in this study 
Gene Forward primer Reverse primer 
ATM ATTCCAGCAGACCAGCCAAT GGTCATCACGGCCCTTAACA 





















































Puma TACGAGCGGCGGAGACAAG GCACCTAATTGGGCTCCATCT 
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2.10 Cell fractionation 
According to Wysocka et al. (Wysocka, Reilly, & Herr, 2001), briefly, 1 × 10
7
 to 2 × 
10
7
 cells were collected, washed with PBS, and resuspended at 4 × 10
7
 cells/ml in 
buffer A [10 mM HEPES pH 7.9, 10 mM KCl, 1.5 mM MgCl2, 0.34 M sucrose, 10% 
glycerol, 1 mM dithiothreitol, and protease inhibitor cocktail (Roche)]. Triton X-100 
was added to a final concentration of 0.1% (v/v). The resuspended cells were 
incubated on ice for 8 min, and nuclei (fraction P1) were collected by centrifugation 
(5 min, 1,300 × g, and 4°C). The supernatant (fraction S1) was clarified by 
high-speed centrifugation (5 min, 20,000 × g, 4°C), and the supernatant (fraction S2) 
was collected. The P1 nuclei were washed once in buffer A and lysed for 30 min in 
buffer B [3 mM EDTA, 0.2 mM EGTA, 1 mM dithiothreitol, and protease inhibitor 
cocktail (Roche)], and insoluble chromatin (fraction P3) and soluble (fraction S3) 
fraction were separated by centrifugation (5 min, 1,700 × g, 4°C). The P3 fraction 
was washed once with buffer B, resuspended in sodium dodecyl sulfate 
(SDS)-Laemmli buffer and boiled for 10 min. 
2.11 Immunoprecipitation 
Cell lysate was extracted in lysis buffer [50 mM Tris-HCl pH 7.5, 0.1 mM EGTA, 1% 
(w/w) Triton X-100, 1 mM sodium orthovanadate, 50 mM sodium fluoride, 5 mM 
sodium pyrophosphate, 0.27 M sucrose, 0.1% (v/v) 2-mercaptoethanol plus 1 
tablet/50 ml of EDTA free complete protease inhibitor cocktail (Roche)]. Protein 
lysates from cells were centrifuged at 14,000 × g for 5 min at 4 °C and the insoluble 
debris discarded. Protein concentrations were determined using Bio-Rad protein assay 
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dye. 10 μl of Flag M2 beads (for Flag IP) (Sigma) or 2 μg of relevant antibody coupled 
to 10 μl of protein G-agarose beads (Thermo Scientific) were washed with 1ml lysis 
buffer before incubation with 1mg total lysate for 1 h at 4 °C on a 1000rpm orbital 
shaker. Proteins bound to the beads were separated from the supernatant by 
centrifugation at 15,000 g for 1 min, washed twice with 1 ml of lysis buffer containing 
0.5 M NaCl and twice with 1 ml buffer B [50 mM Tris-HCl pH 7.5, 0.27 M sucrose and 
0.1% (v/v) 2-mercaptoethanol]. After removing all the remaining supernatant, 
SDS-Laemmli buffer was added to the beads to denature the antibody and release the 
immunoprecipitated protein. The samples were boiled for 10 min before being 
subjected to SDS- PAGE electrophoresis and subsequent Western blotting analysis.  
2.12 Western blotting (Immunoblotting) 
Appropriate amount of lysate samples were electrophoresed on a polyacrylamide gel 
of a percentage dependent on the size of the target protein, transferred onto a PVDF 
membrane in cold room and probed with primary antibodies of interest at 4 °C 
overnight. The following experiment was processed as standard using HRP 
conjugated secondary antibody (Invitrogen) and enhanced chemiluminescence 
visualization method (Thermo Scientific). 
2.13 Recombinant protein expression and purification 
As described previously in Cheung et al (Cheung, Campbell, Nebreda, & Cohen, 2003), 
BL21 DE3 strain transformed with specific GST tagged expression plasmids were 
grown to OD600nm of 0.6 and induced for 16 h at 26°C with 40 µM isopropyl–β-D- 
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thiogalactopyranoside (Sigma). Cells were harvested by centrifugation and 
resuspended in extraction buffer [50 mM Tris–HCl pH 7.5, 0.1 mM EGTA, 150 mM 
NaCl, 0.03% (w/v) Brij-35, 5% (v/v) glycerol, 0.1% (v/v) 2-mercaptoethanol, 0.1 mM 
phenylmethylsulfonyl fluoride, 1 mM benzamidine, 1 mM dithiothreitol]. Before 
further processing, a small portion of samples were subjected to SDS-PAGE and 
stained with Coomassie Blue to verify successful induction of target proteins. The 
harvested cells were subjected to freeze-thaw once and then sonicated for 2 min on ice. 
Triton X-100 was added to a final concentration of 1% (v/v) and the suspension was 
left on ice for 30 min. The cell debris was cleared by centrifugation for 30 min at 
75,000 × g and the supernatant (termed lysate) was decanted. The lysate (30 ml) was 
incubated for 1 h at 4°C with 3 ml of a 50% slurry of Glutathione Sepharose 4B (GE 
healthcare). Then the pellet was washed twice with wash buffer 1 [50 mM Tris–HCl 
pH 7.5, 0.27 M sucrose, 0.5 M NaCl, 0.1% (v/v) 2-mercaptoethanol], followed by 
twice with wash buffer 2 [50 mM Tris–HCl pH 7.5, 10 mM NaCl, 0.27 M sucrose, 0.1% 
(v/v) 2-mercaptoethanol], and eluted with 20 mM glutathione in wash buffer 2. 
Glutathione was removed by dialysis in wash buffer 2. 
2.14 SAM binding assay 
10µg recombinant GST, GST-Mettl8 WT and ΔSAM protein were conjugated to 10 µl 
Glutathione Sepharose 4B at 4°C for 30min before being incubated with 5μl 3H-SAM 
(12-18 Ci/mmol (444-666 GBq/mmol)) at 30°C for 30min. After two washes with 
0.5ml 100mM Tris-HCl pH7.5, the beads were transferred to scintillation tube and 
mixed with 2 ml scintillant cocktail (OptiPhase HiSafe 2, Perkin Elmer). The result 
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was obtained from triplicate reactions on Wallac 1414 Liquid Scintillation counter 
controlled by the WinSpectral software system. 
2.15 Luciferase assay  
Mouse mettl8 promoter -1498bp to 0 region was cloned from C57BL/6 adult liver 
genomic DNA and inserted into pGL4.17 by SacI/BglII sites as pGL4.17-Mettl8b 
vector. Stat3 binding site at -146bp on reverse strand was mutated from ttccgggag into 
ggacgggag (named as pGL4.17-Mettl8bM) by site-directed mutagenesis. 
pGL3-M67-SIE was a gift from Dr. Dominic Voon of NUS. These vectors were 
transfected together with pRL-TK into Stat3 positive liver cells and after 48h cells 
were lysed in passive lysis buffer according to manufacturer’s instruction (Promega 
Dual Luciferase kit) and measured manually in triplicate manner. 
2.16 Chromatin Immunoprecipitation (ChIP) assay 
As described in Lee et al (T. I. Lee, Johnstone, & Young, 2006), briefly 1x10
7
 Stat3 
positive liver cells were treated with 10ng/ml murine oncostatin M (OSM) for 0, 30min, 
1h and 2h and fixed with formaldehyde and neutralized by glycine. Cells were 
harvested in cold PBS and nuclear extract prepared as described. After sonication, 
cleared nuclear lysate was incubated with 2 µg Stat3 antibody conjugated to 20 µl 
protein G agarose for 16h. After extensive wash DNA was reverse cross-linked and 
eluted. For H1650 cells, no treatment was done prior to fixation. 
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2.17 Gene Knockout in cell lines by CRISPR/Cas9  
Vector pST1374-NLS-flag-linker-Cas9 containing human-codon-optimized Cas9 and 
human-gRNA-expression vector MLM3636 were from Addgene. MLM3636 vectors 
with gRNAs targeting human Mettl8 were self-made in our lab following instructions 
of Joung Lab. 
Cells were transiently transfected with Cas9 plasmid and gRNA expression vectors 
using lipofectamine with standard protocols (Chapter 2.4.1). Cells were transfected in 
24-well plates using 0.5 μg of the Cas9 expression plasmid and 0.3 μg of the RNA 
expression plasmid. Two days after transfection, cells were trypsinized and replated in 
10 cm dishes with a highly diluted passage ratio for single clone selection. After 
about two weeks, single clones were picked and cultured in individual wells. 
The selection of positive clones was done first by western blot analysis of Mettl8 
expression. Then genomic DNA of the Mettl8-null clones was extracted by 
phenol-chloroform method, and then subjected to PCR, TA cloning and sequencing to 
confirm the mutation of the Mettl8 gene. 
2.18 Microarray 
Total RNA was harvested and purified by the RNeasy mini kit with on-column 
DNAse digestion (Qiagen) according to the manufacturer’s instructions. The array 
was done using HumanHT-12 v4 Expression BeadChip Kit by our common facility. 
The microarray analysis was carried out using R language by our bioinformatician.  
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Chapter 3 Results 
3.1 Mettl8 as a potential methyltransferase 
In this chapter, we will show how Mettl8 was screened out and the validation of it as 
a Stat3 target. As Mettl8 is a poorly studied protein, we started our research by 
localization study. The ability of Mettl8 to bind SAM molecule is confirmed by in 
vitro assay although the substrate of its potential methyltransferase activity is still 
unknown. 
3.1.1 Mettl8 is a novel target of Stat3 
In order to find more targets of Stat3, we carried out the screening in a pair of 
immortalized mouse liver cells in the presence or absence of Stat3. We created the 
first cell line without Stat3 by clean-cut genetic approach in the laboratory; it’s 
originated from C57BL/6 mouse with transthyretin (TTR)-Cre driven Stat3 deletion 
in adult liver. To make a parallel control, Stat3 is reintroduced into the parental Stat3 
KO cell to generate Stat3+ liver cell. As shown in Figure 11A, Stat3 is clearly not 
detectible in original KO cells and expression is restored in the Stat3+ cells. And 
Stat3 showed expected phosphorylation pattern at Tyrosine 705 when treated with 
murine oncostatin M (OSM), a potent activator for Stat3, as mentioned in the 
introduction.  
With these cells, we screened about 300 genes by qPCR covering epigenetic factors, 
growth factors and transcription factors (list of genes available upon request). A 
number of epigenetic genes showed changed mRNA expression with OSM treatment. 
Chapter 3 Results  
47 
One of them drew our attention: methyltransferase like protein 8 (Mettl8); its mRNA 
level was upregulated about 1.5-fold in Stat3 KO cells with OSM treatment, while it 
increased 2.5-fold in Stat3 positive cells (Figure 11B), comparable to the established 
Stat3 target genes like interferon regulatory factor 1 (IRF1) and suppressor of 
cytokine signaling 3 (Socs3) which are listed as positive control. Given its novelty, 
we decided to look further into this gene. 
By analyzing promoter sequence of this gene, we found two Stat3 consensus sites, 
one is very close (-146bp) to TSS (transcription start site) and the other one is at distal 
region (about 6.2kb upstream). Two AP-1 binding sites are also present at -433 and 
-989bp, which could be accounted for the induction by OSM in the absence of Stat3, 
as OSM can also activate MAPK pathway. To further test the regulation of Stat3, we 
cloned the about 1.5kb promoter region of mouse Mettl8 into pGL4 luciferase 
reporter vector (pGL4-Mettl8-b), and mutated the proximal Stat3 site 
(pGL4-Mettl8-bM), as shown in Figure 11C. The primer amplicon corresponding to 
these two binding sites are listed as P1 (proximal) and P2 (distal).  
Firstly Stat3 ChIP experiment was performed to confirm Stat3 binding on P1 but not 
on P2, as shown in Figure 11D. The binding was induced by OSM treatment 
dramatically at 30min and dropped after 1h, barely detectible at 2h, as revealed by 
PCR and qPCR respectively. Secondly, we tested the promoter reporter in the liver 
Stat3+ cells; the mutation of Stat3 site consistently reduced the activity by 3-fold 
(Figure 11E). However, this promoter could not be induced further by OSM treatment 
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(data not shown), indicating that there may be other components required for full 
Stat3 regulation.  
The human Stat3 consensus site on human Mettl8 is also very close (+524bp) to TSS. 
The primer amplicon corresponding to this binding site is listed as P3 (+446bp to 
+604bp) (Figure 11F). Human Stat3 ChIP experiment was done using H1650 cells, 
which is a non-small cell lung cancer cell line with constitutive Stat3 activation (Song, 
Rawal, Nemeth, & Haura, 2011), so no induce is needed. Stat3 antibody (C-20) has a 
more than 6-fold increase of binding to Mettl8 promoter compared to that of IgG 
antibody (Figure 11G). This experiment was done in collaboration with my colleague 
Miss He Huining. 
These data collectively support that Mettl8 is a novel target of Stat3 in both mouse 
and human, although it is not under exclusive control of Stat3. 
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Figure 11. Mettl8 is a novel Stat3 target gene.  
A) Stat3+ and KO mouse liver cells were established as described in text. 30ug of 
whole cell lysates were immunoblotted with anti-Stat3, Stat3 pY705 and tubulin 
antibodies after stimulation with 10ng/ml murine OSM for indicated period.  
B) mRNA level of mettl8 is detected by qPCR between untreated and OSM 1h treated 
Stat3-/+ liver cells. 
C) Diagram of mouse mettl8 promoter showing the binding site of Stat3, AP-1, and 
PCR products surrounding Stat3 binding sites. Two promoter constructs containing 
wild-type proximal Stat3 site and mutated Stat3 site were listed.  
D) Stat3 ChIP was performed with 10
7
 Stat3+ liver cells treated with OSM for 
different time points. Equal amount of eluted DNA was amplified in normal PCR to 
detect region of two binding site, P1 and P2. A similar sized region on GAPDH gene 
was amplified against input DNA as internal control (upper panel). The same 
experiment was carried out with qPCR to show the enrichment of Stat3 binding site 
as percentage compared to the equal amount of input DNA (lower panel).  
E) Luciferase reporting assay was carried out with pGL3-M67-SIE, pGL4-Mettl8-b 
(wt) and Stat3 binding site mutated vector in Stat3+ liver cell. 
F) Diagram of human mettl8 promoter showing the binding site of Stat3 and PCR 
product surrounding Stat3 binding site.  
G) Human Stat3 ChIP was performed with 10
7
 H1650 cells. Equal amount of eluted 
DNA was amplified in qPCR to show the fold enrichment of Stat3 binding to Mettl8 
promoter compared to IgG control.
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3.1.2 Subcellular localization of Mettl8  
Proteins are responsible for performing the vast majority of cellular functions. Cells 
are highly compartmentalized, restricting most proteins to specific subcellular regions 
or organelles. The localization of a protein is crucial in determining its activity. For 
example, a RNA-binding protein would not be able to bind RNA if it were restricted 
to the cytoplasmic membrane. Thus, determining the subcellular localization of a 
protein within a cell can provide valuable information about its function. 
To better understand the function of Mettl8, we studied its localization in cells by both 
biochemical fractionation and immunostaining methods.  
Mettl8 ΔSAM mutant lost the nuclear localization, compared to the ubiquitous 
distribution of wildtype protein, when HCT116 stable cells with Flag tagged Mettl8 
wild type and ΔSAM mutant proteins were fractionated into nuclear and cytoplasmic 
fractions using established protocol, shown in Figure 12A. Wild type Mettl8 was 
detected by Flag antibody in both cytoplasm and nucleus regardless of irradiation, 
while Mettl8 ΔSAM mutant cannot be found in nuclear fraction, although the part 
deleted did not contain any nuclear localization signal. Alpha-tubulin served as a 
cytoplasmic marker.  
To further confirm the intracellular localization of WT and mutant Mettl8, wild type or 
mutant Mettl8 with both Flag and HA tags were transiently overexpressed in U2OS 
cells by lipofectamine transfection and stained for Mettl8, Flag or HA antibody. All 
three antibodies provided the same staining patterns (data not all shown) and some 
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untransfected cells in the field were negatively stained, showing the specificity of the 
antibodies used. 
Wild type Mettl8 showed ubiquitous pattern with slightly stronger localization in 
nucleus as shown in Figure 12B, regardless of its relative expression level (brightness 
of Mettl8 signal). We notice there are concentrated positive staining areas in nucleus of 
Mettl8 wt cells, which resemble nucleolus pattern. Using a nucleolar marker Fibrillarin, 
we were able to show the colocalization of concentrated Mettl8 signal with nucleolus, 
suggesting Mettl8 may be related to rRNA processing or ribosome biosynthesis (Figure 
12B, left panel). The pS/TQ mutant S405A still possessed the similar pattern as 
wildtype Mettl8 (Figure 12B, right panel).   
Consistent with the fractionation result, ΔSAM mutant cells showed clear exclusion 
from nucleus region (Figure 12C). Like ΔSAM mutant, ΔNRB mutant is unable to 
enter nucleus. However, ΔSANT mutant is still able to localize to nucleus (data not 
shown).  
Unfortunately, we did not have a good antibody to detect endogenous Mettl8 to reveal 
more physiologically relevant information.  
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Figure 12. Subcellular localization of overexpressed wt and mutant Mettl8 
proteins. 
A) HCT116 cells with stably overexpressed Flag-Mettl8 wt, and SAM mutant were 
fractionated into cytoplasmic (Cy) and nuclear extract (Nu). Equal amount of lysates 
were resolved on SDS-PAGE for immunoblotting with anti-Flag, α-tubulin and Actin 
antibodies. *indicates the remained signal of Flag IB.  
B) WT or S405A Flag-Mettl8 were transfected into U2OS cells by lipofectamine and 
stained for Mettl8 (red) or Fibrillarin (green) antibody and counter stained with DAPI 
(Blue). One representative picture was shown. The scale bar indicates 10µm. Slides 
were visualized using a Nikon A1confocal microscope. 
C) Flag-Mettl8 SAM was transfected into U2OS cells by lipofectamine and stained 
for Flag (red) and counter stained with DAPI (Blue). Three independent pictures were 
shown in the figure. The scale bar indicates 10µm. Slides were visualized using a 
Nikon A1confocal microscope.
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3.1.3 Mettl8 is a potential methyltransferase with unknown substrate 
As mentioned in the introduction, it is very challenging to identify a substrate for a 
novel and putative SAM dependent methyltransferase (MTase). However there is an 
essential function which can be tested rather easily: whether it can bind the methyl 
donor molecule S-adenosylmethionine (SAM).  
For that purpose, GST-tagged wild type and SAM mutant of human Mettl8 were 
expressed and purified from E.coli, as shown in Figure 13A; purification was 
successful with some degradation product below the major band of GST-Mettl8. Then 
we tested the ability of Mettl8 to bind SAM, using 
3
H-labeled SAM. Briefly, 
immobilized GST, GST-Mettl8 wt and SAM on Glutathione Sepharose 4B beads 
were incubated with 
3
H-SAM and measured by standard liquid scintillation method 
after extensive wash. As shown in Figure 13B, GST beads or GST protein alone 
showed basal level of background activity, while GST-Mettl8 wt showed 14-fold 
increase. Mutation of SAM domain disrupted the binding ability of GST-Mettl8 to 
SAM molecule as the reading was back to background level. More interestingly, 
autoradiograph of the duplicate binding reaction showed that wt GST-Mettl8 was 
labeled by 
3
H-SAM at the size of itself, suggesting that Mettl8 auto-methylation 
occurred (Figure 13C).  
Since later we found Mettl8 forms complex with p53 and core histones (Chapter 3.2.2), 
we then tested whether they could be methylated by Mettl8 in vitro. However, we could 
not detect any labeling of GST-p53 by Mettl8 (data not shown). Although H2A and H4 
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could be labeled by Flag-Mettl8 IP from 293T cells, it could be due to contaminants 
co-purified such as PRMT5 as PRMT5 is readily pulled down by Flag M2 beads (data 
not shown). 
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Figure 13. Mettl8 is a potential methyltransferase.  
A) GST, GST-Mettl8 wt and SAM mutant were expressed and purified from E.coli 
BL21 strain by Glutathione Sepharose 4B and resolved on SDS-PAGE. The proteins 
were visualized by Coomassie staining.  
B) Equal amount (10mg) of GST, GST-Mettl8 wt and mutant proteins were 
conjugated on Glutathione Sepharose 4B beads and incubated with 
3
H-SAM for 
30min at 30°C with empty beads as control. After extensive wash with 10mM Tris-Cl 
pH7.5, the beads were transferred to scintillation tubes and measured on liquid 
scintillation counter in triplicate manner.   
C) Similar to B), the beads after incubation with 
3
H-SAM were resolved on 
SDS-PAGE and subject to autoradiography at -80°C for 48h. 
All the radioactive work was done by Dr. Liu Xinyu.
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3.1.4 Discussion 
There are several criteria for identifying a Stat3 target gene. The first one is the 
presence of an evolutionarily conserved Stat3 binding consensus motif (Ehret et al., 
2001) in the promoter or enhancer regions of a gene of interest. This requirement was 
met in Mettl8 as shown by both gene promoter analysis and ChIP assay and promoter 
reporter assay experimentally. A second commonly presented form of evidence is that 
constitutively active mutant form of Stat3 induces the expression of the given gene, 
which in our case we used OSM treatment instead to activate Stat3, which could 
indeed induce Mettl8 expression (Figure 11B). Another way of identifying a role for 
Stat3 in the transcriptional regulation of a particular gene is to show that acute genetic 
deletion of Stat3 gene results in the loss of target gene expression. Mettl8 mRNA 
level is similar in Stat3 KO and Stat3+ cells (Figure 11B), suggesting the existence of 
other transcription factors (TFs) in regulating Mettl8. Whether or not these TFs 
cooperatively work with Stat3 needs further studies. 
The entry and exit of large molecules from the cell nucleus is tightly controlled 
(Silver, 1991). Transporting most of the nuclear proteins to the cell nucleus of a 
eukaryotic cell relies on specific nuclear localization signals (NLSs) that are 
recognized by protein import receptors. NLSs are generally short sequences of 3–20 
amino acid residues, normally rich in lysine and arginine (Dingwall & Laskey, 1991). 
An NLS is a cluster of basic amino acids, which can be monopartite or bipartite. 
Monopartite NLS contains a single cluster of basic residues, and bipartite NLS 
contains two clusters of basic residues separated by a 10–12 residue linker. A 
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consensus sequence that represents the diversity of NLSs is a monopartite NLS 
sequence where a required lysine residue is followed by two other basic residues in 
the sequence K-(K/R)-X-(K/R), where X is any amino acid (Hodel, Corbett, & Hodel, 
2001). The NLS of mouse Mettl8 protein is LRFKKGRCL, which fits the consensus 
requirement. The NLS of human Mettl8 protein LRFKKGHCL has a histidine instead 
of lysine or arginine, all three of which are basic amino acids. The NLS must be 
exposed on the protein surface to be accessible for the nuclear protein import receptor 
complex. And access to a protein’s NLS can be regulated by phosphorylation, 
ligand-induced conformational changes, or intermolecular masking of target 
sequences (Jans, Xiao, & Lam, 2000). Although Mettl8 ΔSAM or ΔNRB mutant still 
possesses the NLS, they may have some unknown modification or conformation 
changes that prevent them from being imported into nucleus. 
It is often the case that the initial structural and domain analysis at best indicates a 
potential function for a given unknown protein, but further identification of a relevant 
ligand or substrate is impeded by the diversity of possible functions in a specific 
structural classification of protein family. Although we confirmed the SAM binding 
activity of Mettl8 protein, it is still challenging to find the substrate. However, given 
the particular cellular localization of human Mettl8 protein and that its close family 
member mettl2’s homolog ABP140 is a tRNA MTase in Saccharomyces cerevisiae 
(Noma et al., 2011), it is possible that RNA might be the substrate for the 
methyltransferase activity of Mettl8, which is currently being tested. 
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3.2 Mettl8 and ATM 
3.2.1 Mettl8 is an ATM substrate 
As mentioned in the introduction, the C-terminus of Mettl8 sequence STLLSQD fits 
with all the requirements for being a substrate of the PIKK family. Interestingly, this 
motif is only present in human Mettl8, but not mouse Mettl8 or human Mettl2, 
reminiscent of the variance observed of some key factors of DDR such as BRCA1.  
To test this possibility, we established stable HCT116 cells with Flag tagged human 
Mettl8 and treated the cells with various DNA damaging stimulations, such as UV, 5’ 
Fluorouracil (5’ FU), cisplatin, etoposide or gamma irradiation at 1 and 10Gy. Indeed, 
human Mettl8 was found to be phosphorylated at pS/TQ motif with gamma irradiation 
and etoposide treatment which both cause double strand breaks on DNA, while other 
DNA damaging agent or treatment did not cause significant pS/TQ phosphorylation, as 
shown in Figure 14A. Phosphorylation of p53 at Ser15 was found in all stimulation 
except for UV and this site has been reported to be phosphorylated by different kinases: 
ATM, ATR and DNAPKcs (Meek, 2009).  Phosphorylation of Chk2 at Thr68 was 
found in cell lysates with DSB only: irradiation and etoposide, which correlated well 
with ATM activation as shown by ATM autophosphorylation at Ser1981. Similar result 
was also obtained from 293T cell (data not shown) indicating that this effect is not 
HCT116 cell specific. As expected, mouse Mettl8 and human Mettl2, which do not 
have pS/TQ motif, treated with irradiation did not show phosphorylation at pS/TQ 
motif (data not shown). This result demonstrates that human Mettl8 is readily 
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phosphorylated in DSB response which predominantly activates ATM at the early time 
point used here.  
We then checked if ATM is the responsible kinase for Mettl8 pS/TQ phosphorylation. 
Chemical inhibitors of general PIKK Wortmannin, a widely used ATM specific 
inhibitor Ku55933, along with Chk1/2 inhibitor AZD7762 were used to pretreat 
HCT116 Flag-Mettl8 stable cells for 1h before gamma irradiation. As shown in Figure 
14B, only Wortmannin and Ku55933 pretreated samples showed significantly reduced 
phosphorylation on KAP1 Ser824 and Chk2 Thr68 which had been proven to be ATM 
substrate sites. The autophosphorylation of ATM at Ser1981 was only specifically 
inhibited by Ku55933, but not wortmannin, which is consistent with different 
mechanisms of these two chemicals: wortmannin covalently modified the phosphate 
transfer site (Wymann et al., 1996), while Ku55933 is an ATP binding competitor for 
ATM kinase (Hickson et al., 2004). As expected, pS/TQ of Mettl8 after 10Gy IR was 
dramatically reduced by pretreatment with wortmannin and Ku55933, suggesting this 
pSQ motif is indeed phosphorylated by PIKK and ATM is the major responsible kinase. 
As Ku55933 at 10μM could also inhibit DNAPKcs’ activity (IC50 about 5μM) 
(Hickson et al., 2004), we further tested dose response to Ku55933 on Mettl8 
phosphorylation by IR. As shown in Figure 14C, 1μM Ku55933 was sufficient to 
prevent the phosphorylation of Mettl8, confirming that ATM is the kinase responsible. 
To confirm whether Ser 405 on human Mettl8 is the only pS/TQ motif or there exist 
other sites, we performed site-directed mutagenesis to change Ser 405 into Ala and 
repeated the experiment in 293T cells. As shown in Figure 14D, upon irradiation 
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pS/TQ phosphorylation was detected on wild type Mettl8 only, but not S405A mutant. 
This result points out that Ser 405 is the only pS/TQ motif on Mettl8 and validates the 
bioinformatics motif analysis result.  
To test if the SANT and SAM domain are required for optimal pS/TQ phosphorylation, 
we generated HCT116 cells with stably expressed Flag mettl8 ΔSANT and ΔSAM. 
Interestingly, ΔSANT Mettl8 showed pS/TQ phosphorylation as wild type Mettl8 
although ΔSANT Mettl8 expression level was much lower than wild type, while 
ΔSAM Mettl8 cannot be phosphorylated at pS/TQ anymore, as shown in Figure 14E. 
This difference could be related to their specific subcellular localizations and functions 
in cell. 
Combined with previous results of subcellular localization of Mettl8 WT and ΔSAM 
mutant (Figure 12), we can conclude that the phosphorylation of pS/TQ motif on 
Mettl8 should take place in nucleus. Collectively we showed that human Mettl8 is a 
new substrate of ATM and the phosphorylation site is Ser 405. 
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Figure 14. Human Mettl8 is a substrate of ATM. 
A) HCT116 stable cells with Flag human Mettl8 protein were treated with various 
DNA damage agents (UV 100J/m2, recovered for 6h; 5’FU 25μM, 6h; cisplatin 
30μg/ml, 6h; gamma irradiation at 1Gy or 10Gy, recovered for 1h; etoposide 10μM, 
6h). Then equal amount of lysates were subjected to Flag IP with M2 beads and 
washed extensively before being resolved on SDS-PAGE and followed by 
immunoblotting with anti-pS/TQ motif antibody. The lysates were immunoblotted 
by indicated antibodies. The result is representative of three independent repeats.   
B) Same cells as in A) were pretreated for 1h with Wortmannin (5µM), Ku55933 
(10µM), AZD7762 (0.5µM) or DMSO as the vehicle control; then they were 
irradiated at 10 Gy and harvested 1h later without medium change. Similar to A), 
equal amount of lysates were subjected to Flag IP and probed for anti-pS/TQ and 
Mettl8 antibody. The lysate was immunoblotted by antibodies indicated.  
C) Same cells as in A) were pretreated for 1h with different doses of Ku55933 as 
indicated; then they were irradiated at 10 Gy and harvested 1h later without 
medium change. Similar to A), equal amount of lysates were subjected to Flag IP 
and probed for anti-pS/TQ and Flag antibody. The lysate was immunoblotted by 
antibodies indicated. 
D) 293T cells transfected with WT Flag-Mettl8 and S405A mutant were irradiated 
at 10Gy and harvested 1 hour later, together with untransfected cells. Equal amount 
of lysate were subjected to Flag immunoprecipitation and probed for pS/TQ and 
Flag antibodies.  
E) HCT116 cells with stably overexpressed Flag-Mettl8 WT, ΔSANT, and Δ SAM 
were irradiated at 10Gy and equal lysates were subjected to Flag IP and probed for 
pS/TQ and Flag antibodies. The lysates were probed with Flag and Actin antibodies.
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3.2.2 Mettl8 binds to ATM, p53 and core histones 
Since Mettl8 is a substrate of ATM, it’s natural to speculate whether they could form 
complex. We tried and found it hard to co-express ATM and Mettl8 variants in 293T 
cells. So Flag-ATM and Mettl8 wt or mutants were expressed separately in 293T cells 
and some of the cells were treated by 10 Gy irradiation followed by 1h recovery; the 
lysates were then mixed equally for in vitro binding assay. Flag-ATM was 
immunoprecipitated. Both wt Mettl8 and Mettl8 with mutated or phospho-mimic pSQ 
site were found to associate with ATM in untreated condition and after irradiation 
(Figure 15A). We then looked at the reciprocal immunoprecipitation of Flag-Mettl8. 
Endogenous ATM was detected in resting state and after irradiation (Figure 15B). In 
both IPs, a very mild reduction of the association between ATM and Mettl8 was 
found when cells were irradiated. We can conclude that ATM and Mettl8 could form a 
complex.  
As SANT domain has been reported to recruit p300 which is a key co-factor for a 
number of transcription factors such as p53 and acetylates both histone and p53 (Gu 
& Roeder, 1997), and ATM was able to bind and phosphorylate p53 (Khanna et al., 
1998), we went on to test whether p53 could be associated with Mettl8. In 
co-immunoprecipitation experiment, endogenous p53 was readily detectible in Flag 
IP of overexpressed Mettl8 in 293T cells, as shown in Figure 15C. Moreover, 
phospho-S15 p53 was also found in Flag IP of Mettl8, either wild type or S405A 
mutant, as shown in Figure 15D, and histone H3 was also found to bind Mettl8, along 
with other core histones (data not shown). This result is further confirmed in 293T 
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endogenous IP with Mettl8 antibody (Figure 15E), pointing to a constitutive complex 
between p53, mettl8 and ATM.
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Figure 15. Mettl8 forms complex with ATM, p53 and core histones. 
A) 293T cells overexpressed with Flag-ATM or Mettl8-HA variants were treated by 
IR and left in recovery as indicated. In vitro binding of Flag-ATM and Mettl8-HA 
variants was done by mixing lysates equally as shown in the figure. Flag-ATM was 
then immunoprecipitated. The lysates from IP were then subjected to IB with ATM 
and Mettl8 antibodies. 40µg lysate was checked in immunoblotting for Mettl8 variants 
expression, with heat shock protein 90 (Hsp90) as loading control. 
B) Flag-Mettl8-HA was over-expressed in 293T and immune-purified by M2 beads 
after irradiation with 10Gy for various time points. The samples were subjected to 
immunoblotting with ATM, Flag and pS/TQ antibodies. 40µg lysate was checked in 
immunoblotting for ATM and Flag expression, with Hsp90 as loading control.  
C) Similar to B), lysates immune-purified by M2 beads were eluted with 3X Flag 
peptide and then subjected to immunoblotting with p53, HA and pS/TQ antibodies.  
D) 293T normal cells or overexpressed with wt and S405A mutant of Flag-Mettl8 were 
irradiated with 10Gy dose and equal amount of lysates were subjected to Flag IP and 
subsequent immunoblotting with anti-p53 pS15, Flag and histone H3 antibodies.  
E) 293T normal cells were irradiated with 10Gy dose and equal amount of lysates were 
subjected to Mettl8 IP and subsequent immunoblotting with p53 (DO-1) and Mettl8 
antibodies. 40µg lysate of each sample was checked for p53 (DO-1), Mettl8, p53 pS15, 
and Actin antibodies side by side with IP.
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3.2.3 Mettl8 modulates ATM-p53 pathway in response to irradiation 
As we have shown that Mettl8 is a substrate of ATM and it forms complex with ATM 
and p53, both of which belong to the tumor suppressor pathway in response to DNA 
damage, it will be intriguing to study whether Mettl8 could modulate this pathway. As 
mentioned in the introduction chapter, p53 is a key factor downstream of DNA damage 
to execute the cell fate regulation; its stability and transcriptional activation are tightly 
regulated by phosphorylation at N-terminal Ser 15 by ATM in IR (Cao et al., 2006; 
Hirao et al., 2002; Matsuoka et al., 2007), and acetylation at C-terminus by p300/PCAF 
(Ito et al., 2001; Xie et al., 1998). 
3.2.3.1 Mettl8 ΔSAM mutant affects ATM-p53 DDR 
In a time-course study after 10 Gy of gamma irradiation for stable HCT116 cell lines: 
empty vector, wild type, SAM mutant as shown in Figure 16A, p53 phosphorylation 
at Ser 15 in response to IR was enhanced in Mettl8 mutant cells with SAM mutation, 
compared to wild type and empty vector control. Consistently, acetylation at Lys 382 
on p53 also showed similar pattern as phosphorylation on Ser 15. The stability of 
total p53 did not change as dramatic as Ser15 phosphorylation between Mettl8 mutant 
and wild type. Chk2 phosphorylation by ATM was changed slightly in mutant cells, in 
that the activation was much shorter than wild type, however, the intensity was higher. 
This mild change of Chk2 activation is consistent with total p53 level change in 
mutant Mettl8 cells, as Chk2 can help stabilize p53 by phosphorylating Ser20 of p53 
and disrupting MDM2-p53 binding (S.-Y. Shieh, Ahn, Tamai, Taya, & Prives, 2000). 
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Strikingly, p21, the established target of p53, was induced significantly in Mettl8 
mutant cells, even at basal level without any irradiation in SAM mutant cells. These 
results suggest that Mettl8 affects the trans-activation ability of p53 by modulating its 
acetylation and phosphorylation after gamma irradiation.  
Since p53 Ser15 is a substrate site of ATM in this situation, we then traced upstream 
to ATM activation. The autophosphorylation at Ser1981 is hallmark of ATM 
activation (Bakkenist & Kastan, 2003). Indeed it was upregulated in mutant cells 
compared to wild type Mettl8 cells, as shown in Figure 16B. Phosphorylation of 
heterochromatin factor KAP1, another substrate of ATM, was also found to be 
elevated in mutant cells (Figure 16B), suggesting that Mettl8 may be involved in the 
heterochromatin repair.  
H2AX, a marker for DNA damage was also substantially more activated in SAM 
mutant cells, compared to empty vector or wild type Mettl8, as shown in Figure 16C, 
by staining the cells with γH2AX antibody. Brighter and more foci of γH2AX were 
observed in mutant cells, even without irradiation, which may be due to the much 
more activated ATM pS1981 in both untreated and irradiated mutant cells (Figure 
16B), as it was shown in in vitro assay that γH2AX level increases as ATM activation 
increases (J. H. Lee & Paull, 2004).  
To check if the histone marks were changed during this process, the chromatin 
fraction of HCT116 stable cells with WT Mettl8 or ΔSAM mutant was analyzed for 
certain markers, as shown in Figure 16D. ATM autophosphorylation and p53 
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phosphorylation at Serine 15 were found to be stronger in mutant cells, as well as 
H2AX, which was consistent with previous result shown in Figure 16 (A, B and C). 
Global H3K9 acetylation, trimethylation and H4K20 dimethylation mark were not 
changed between wild type and mutant cells, in line with published data (Tjeertes, 
Miller, & Jackson, 2009). Strikingly, H2AX total level was much higher in mutant 
cells compared to wild type, while H2A, H3 core histone were not changed. This is a 
very interesting result as it may suggest the global level of H2AX isoform in 
chromatin is affected by Mettl8. This could alter the chromatin structure in some way 
favoring the more sensitive detection of DNA damaging signals. 
To make sure the effect of ΔSAM mutant Mettl8 on ATM-p53 DDR is not a 
false-positive result in one set of stable cell clones by accident, another independent 
set of HCT116 stable cells were generated and all the results were reproducible (data 
not shown). 
Next we ask whether pS/TQ motif is required for Mettl8 function to activate ATM 
kinase, mettl8 wildtype, SAM mutant, S405A or S405E and double mutant of S405 
and SAM domain were tested in 293T cells, as shown in Figure 16E. ΔSAM mutant 
showed enhanced ATM activation compared to wildtype, which is consistent with 
result obtained from HCT116 cell in Figure 16A, suggesting this is not cell type 
specific. S405A mutant showed enhanced ATM phosphorylation at 15min after IR, 
but it quickly diminished from 30 to 60 min after IR. On the contrary, S405E, the 
phospho-mimic mutant showed reverse effect that ATM activation was delayed but 
prolonged. S405A and SAM double mutant cells showed even higher activation of 
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ATM than each single mutant, and the effect was lasting longer. S405E and SAM 
double mutant showed shorter activation of ATM, which was different from each 
single mutant phenotype. The other two ATM substrates KAP1 and Chk2 
phosphorylation patterns were not changed significantly. These results showed the 
pS/TQ motif on Mettl8 could affect ATM activation in a distinct manner compared to 
ΔSAM mutant which was dominant. 
In an attempt to scan for genome-wise change in the HCT116 stable cells with Mettl8 
ΔSAM mutant, we carried out a whole genome microarray analysis for them. In the 
list, we found ATM gene is slightly upregulated, along with many other genes (data 
not shown). To validate the result, we checked the whole cell lysate of stable mutant 
cells. To our great surprise, as shown in Figure 16F, total H2AX and ATM protein 
level was upregulated in ΔSAM mutant cells compared to wild type cells. This result 
was supported further by qPCR analysis, showing that ATM and H2AX was 
upregulated in ΔSAM cells compared to wild type and empty vector control at 
unstimulated situation. After 10Gy IR for 24h, the upregulation is not significant 
between empty vector and ΔSAM mutant cells, while wild type Mettl8 showed 
certain suppression (Figure 16G).   
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Figure 16. SAM Mettl8 mutant affects ATM-p53 DDR. 
A&B) HCT116 stable clones with Mettl8 variants were irradiated at 10Gy and left 
in recovery for the time indicated. Equal amount of lysates were resolved on 
SDS-PAGE and immunoblotted against indicated antibodies. The same lysates 
were used in Figure A&B. 
C) Same cells as in A). Cells were irradiated at 1 or 10Gy and left in recovery for 1h 
before standard immunostaining procedure with γH2AX antibody and counter stain 
with DAPI. Images were presented after Z-stack processing by Nikon A1 confocal 
microscope.  
D) The indicated stable cells were irradiated at 10Gy and left in recovery for the 
time indicated. Chromatin fraction was extracted from the cells. Equal amount of 
sample was resolved on SDS-PAGE and immunoblotted against indicated 
antibodies. 
E) 293T cells transiently transfected with Mettl8 WT and variants indicated in the 
figure were irradiated at 10Gy and left in recovery for the time indicated. Equal 
amount of lysates were resolved on SDS-PAGE and immunoblotted against 
indicated antibodies. 
F) Same cells as in D). Total cell lysates were prepared by solubilizing cells in 
1×SDS sample buffer and then subjected to WB with indicated antibodies. 
G) Same cells as in A). RNA was extracted and reversed for qPCR analysis with 
indicated primers.
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3.2.3.2 Mettl8&Mettl2 Double knockdown affects ATM-p53 DDR 
To validate the results related to ΔSAM mutant Mettl8 in endogenous condition, we 
established lentivirus mediated shRNA knockdown (KD) cells. Five different 
shRNAs were tested for Mettl8 and Mettl2 respectively in HCT116 cells. The KD 
efficiency of Mettl8 shRNAs was evaluated in western blot (Figure 17A); shRNA2 
was picked for further experiment. Since we don’t have a good Mettl2 antibody to 
detect endogenous Mettl2, only qPCR was done to select the best shRNA targeting 
Mettl2 (both Mettl2A&B) (data not shown) and the one with best KD efficiency 
(shRNA2) was used for further experiment.  
There is little enhancement of ATM phosphorylation at Ser1981 as early as 15min 
after irradiation in Mettl8 KD sample compared to scramble control, however, 
significant activation of ATM phosphorylation was found in double KD (DKD) 
samples of both Mettl8 and Mettl2, its close family member (Figure 17B), suggesting 
that there might be some redundant role between them. Strikingly, phosphorylation of 
ATM was observed even without irradiation in double KD sample, and total ATM 
level was also elevated in double KD samples compared to scramble control which is 
consistent with observations in ΔSAM mutant cells. The specificity and efficiency of 
knock down was validated by qPCR (Figure 17C). 
The mRNA level of ATM and H2AX remained unchanged between double KD cells 
and scramble control (data not shown).
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Figure 17. Mettl8 and Mettl2 double KD affects ATM-p53 DDR. 
A) HCT116 cells were infected with six kinds of lentiviruses, each harboring one 
shRNA against Mettl8 or scramble control, for 72 hours. Then cells were harvested 
in lysis buffer. Equal amount of lysates were resolved on SDS-PAGE for 
immunoblotting against Mettl8 and Actin antibody. 
B) HCT116 cells were infected with lentiviruses harboring shRNA(s) against 
Mettl8 (M8), Mettl2 (M2), both Mettl8 and Mettl2 (M8+2), or scramble control for 
72 hours before irradiation at 10Gy for the time indicated. Equal amount of lysates 
were resolved on SDS-PAGE for immunoblotting against indicated antibodies.  
C) Same cells as in B). RNA was extracted and reversed for qPCR analysis with 
indicated primers.
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3.2.3.3 Mettl8 KO affects ATM-p53 DDR 
To further and more thoroughly elucidate the function of Mettl8, Mettl8 knockout 
(KO) C57BL/6 mouse is being generated from outside source. However, even if we 
have the Mettl8 KO mouse, we still need a Mettl8 KO human cell line for our ATM 
and DDR study, as the mouse Mettl8 protein does not have pS/TQ motif. 
Again, to validate the results related to ΔSAM mutant Mettl8 in endogenous 
condition, we used CRISPR/Cas9 technique, a new affordable genome editing tool 
(Cong et al., 2013; Mali et al., 2013), to generate human cell lines with Mettl8 
knockout. Three pairs of guide RNA (gRNA) targeting different regions of the Mettl8 
genomic DNA (gDNA) were used to knockout Mettl8 in both HCT116 and 293T cells. 
The translation start site ATG is located in Exon 2; gRNA 1, 2, 3 targets boundary 
between intron and Exon 2, Exon 3 and Exon 4 respectively (Figure 18A).  
Only one positive stable clone was obtained for each cell line besides control cells: 
HCT116 with gRNA 3 and 293T with gRNA 1, the knockout effect of which were 
shown by western blotting and gene sequencing (Figure 18B). The HCT116 positive 
clone has an 8bp deletion in the Exon 4 coding sequence. The 293T positive clone has 
a 12bp deletion across the boundary of intron and Exon 2, 6bp before the translation 
start site ATG, which might result in abnormal mRNA splicing. The Mettl8 protein 
can no longer be detected in these two positive KO clones. 
In all time points after irradiation (15min, 30min and 60min), in both HCT116 and 
293T cells, there was significant activation of ATM phosphorylation at S1981, KAP1 
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pS824, Chk2 pT68 and p53 pS15 in Mettl8 KO samples compared to control (Figure 
18C&F). The increase of Chk2 pT68 activation pattern was not observed in ΔSAM 
mutant HCT116 cells previously (Figure 16A); it is possibly due to the different time 
points of sample harvest. Strikingly, a dramatic total ATM level elevation was 
observed in all Mettl8 KO samples with or without irradiation which is consistent 
with observations in ΔSAM mutant cells and Mettl8&Mettl2 double KD cells.  
However, there was only a minor increase of ATM mRNA level in Mettl8 KO cells 
compared to control cells, suggesting that the upregulation of ATM protein level is 
not mainly due to positive transcription regulation (Figure 18E). It was the same case 
with H2AX mRNA and protein level change (Figure 18D&E). H2AX was also more 
activated in Mettl8 KO cells after irradiation compared to control cells, as shown by 
probing against γH2AX antibody (Figure 18D), which is consistent with the more 
activated ATM pS1981 after irradiation in Mettl8 KO cells (Figure 18C). However, 
p21 expression level and pattern was the same in Mettl8 KO cells and control cells 
after irradiation; there was even more p21 protein in control cells without irradiation.  
After validation of the effect Mettl8 ΔSAM mutant or Mettl8 KO has on ATM and its 
downstream DDR pathway, we then went further to confirm that the ATM 
downstream pathway changes were a direct result of ATM activation change, not 
because of regulation by Mettl8 on each pathway component. As shown in Figure 
18G, ATM inhibitor Ku55933 (10μM) pretreatment can eliminate the activation of all 
the shown ATM substrates, and this result is perfectly consistent between HCT116 
Mettl8 overexpression stable cells and Mettl8 KO stable cells.




Target Sequence Region 
gRNA 1 TAACTTTTTAGGTACTGCTT 
exon2 
gRNA2 CTCAGCTGTGCGAGTCCTTC exon3 
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Figure 18. Mettl8 knockout affects ATM-p53 DDR. 
A) Schematic map of guide RNA (gRNA) target location on the gene of human Mettl8 
(upper panel). Sequences of the three gRNAs used (lower panel). 
B) Upper panel: Equal amount of lysates from HCT116 and 293T control cells and 
Mettl8 KO cells were subjected to WB using Mettl8 and Hsp90 (loading control) 
antibodies.  
Middle panel: Sequencing result of HCT116 Mettl8 KO positive clone. Three TA 
clones (gR7-1,2,3) were sequenced and blasted against intact gDNA sequence.  
Bottom panel: Sequencing result of 293T Mettl8 KO positive clone. Three TA clones 
were sequenced and blasted against intact gDNA sequence. The results were the same. 
Only one clone (seq 2) is shown. The translation start ATG is shown in a box. The 
boundary between intron and exon 2 is indicated by a reverse ^ symbol.  
C) HCT116 control cells and Mettl8 KO cells were irradiated at 10Gy and left in 
recovery for the time indicated. Equal amount of lysates were resolved on SDS-PAGE 
and immunoblotted against the various antibodies listed.  
D) Same cells as in C). Total cell lysates were prepared by solubilizing cells in 
1×SDS sample buffer and then subjected to WB with indicated antibodies. H2A 
and Actin were used as loading control. 
E) Same cells as in C). Cells were irradiated at 10Gy and left in recovery for 24h, and 
then were harvested in Trizol. RNA was extracted and reversed for qPCR analysis with 
indicated primers. 
F) 293T control cells and Mettl8 KO cells were irradiated at 10Gy and left in recovery 
for the time indicated. Equal amount of lysates were resolved on SDS-PAGE and 
immunoblotted against indicated antibodies. 
G) Untreated HCT116 stable cells with WT or ΔSAM Mettl8, and ΔSAM Mettl8 stable 
cells pretreated with Ku55933 (10µM) for 1h were irradiated at 10 Gy and left in 
recovery for the time indicated. Equal amount of lysates were subjected to 
immunoblotting against antibodies indicated (left). Same experiments were done with 
Mettl8 KO and control HCT116 cells.
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3.2.4 Mettl8 expression in DNA damage response 
After establishing Mettl8 as an ATM substrate and its role in regulating ATM-p53 
pathway in DDR, we wondered how Mettl8 itself would change in response to DNA 
damages. 
We found that there was no significant change of Mettl8 protein expression level in 
HCT116 cells within 24 hours in response to 10 Gy IR which caused DSB (Figure 
19A). Then we tested Mettl8 protein expression in DNA crosslinks damage induced 
by different doses of cisplatin in 293T, HCT116 and HepG2 cells. As shown in Figure 
19B, Mettl8 expression remained the same when cisplatin concentration increased 
from 0μM to 30μM in all three cell lines tested. Interesting Mettl8 expression was 
found to be downregulated by an increase of cisplatin concentration from 30μM to 
60μM. In HepG2 cells, Mettl8 expression was not further downregulated when 
cisplatin concentration went further up to 100 or 150μM. In 293T and HCT116 cells, 
Mettl8 expression was further suppressed when cisplatin concentration went up from 
60μM to 100μM, but did not change between 100μM and 150μM treatment. This 
result showed that Mettl8 was downregulated in DNA crosslinks damage caused by 
cisplatin in a dose dependent manner by an unknown mechanism. 
Cisplatin is a widely used anticancer agent in the treatment of solid tumors (Basu & 
Krishnamurthy, 2010). And interestingly upregulation of ATM transcription level was 
previously reported as a response to DNA crosslinks damage (Yamamoto et al., 2008). 
Future studies on the role of Mettl8 in cellular response to cisplatin-induced DNA 
damage may help decide cisplatin sensitivity in cancer therapeutics.






Figure 19. Mettl8 expression level change in different DNA damage response. 
A) HCT116 cells were irradiated at 10Gy, and left in recovery for the time indicated. Equal 
amount of lysates were resolved on SDS-PAGE and immunoblotted against Mettl8 and Hsp90 
antibodies. 
B) 293T, HCT116 and HepG2 cells were treated with various doses of cisplatin (0, 10, 30, 60, 
100, 150μM) for 24h. 40ug lysates were resolved on SDS-PAGE and immunoblotted against 
Mettl8 and Hsp90 antibodies.
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3.2.5 Discussion 
In this part, we validated Mettl8 as an ATM substrate and its binding with ATM, p53 
and histones. The role of Mettl8 in upregulation of ATM expression and activation, 
and its downstream pathways was shown consistently under three circumstances: 
ΔSAM mutant，Mettl8&Mettl2 double KD and Mettl8 KO. By using ATM inhibitor 
Ku55933, we also showed clearly that the ATM downstream pathway changes were 
directly affected by ATM. Several mechanisms of ATM activation have been reported 
in literature, such as the direct recruitment of ATM by MRN complex (J. H. Lee, 
Goodarzi, Jeggo, & Paull, 2010), and TIP60 mediated acetylation of ATM (Kaidi & 
Jackson, 2013; Sun et al., 2005). What we found about Mettl8 is a new mechanism for 
IR induced ATM activation. 
Many substrates of ATM are recruited into protein network upon their phosphorylation, 
showing the coordinating role of ATM to assemble the cascade of signaling events. 
Some substrate phosphorylation could modulate ATM activation in feedback loop, 
such as NBS1. In our study, we found S405 mutant of Mettl8 showed certain effect to 
regulate ATM activation, although the strongest effect was observed in ΔSAM mutant 
(Figure 16E), as profound as Mettl8 KO and much more profound than Mettl8 KD 
experiment. The discrepancy could partially be due to insufficient KD of Mettl8 and 
compensative role from its family member Mettl2.  
Our results suggested that in the two cells studied Mettl8 protein level is not crucial in 
ATM regulation, as neither Mettl8 KD nor Mettl8 wt overexpression had any effect, 
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unless Mettl8 protein expression was completely abolished by knockout. The SAM 
mutation only disrupts the binding ability to SAM donor molecule, but leaves the rest 
part intact which could be responsible for substrate binding. Thus it may be a potent 
dominant negative mutant. ΔSAM mutant showed substantial effect even at low 
expression level with the presence of endogenous Mettl8 wt protein which has a much 
higher protein level, suggesting that the enzymatic function of Mettl8 is critical and 
dominant negative effect could be more detrimental than protein level change. Whether 
the SAM domain of Mettl2 protein has similar effect is not covered in the current 
study, but it is an interesting question for future research. 
After we discovered the upregulation of ATM protein level along with ATM 
hyperactivation, we tried to figure out the underlying mechanism. ATM promoter is 
under regulation of CpG methylation in HCT116 cells (W. J. Kim, Vo, Shrivastav, 
Lataxes, & Brown, 2002), however, Mettl8 mutant does not affect the methylation of 
ATM (data not shown). Although in ΔSAM mutant and Mettl8&Mettl2 double KD 
HCT116 cells, ATM mRNA level increase was observed in line with protein level 
increase, the fold change of mRNA level was quite minor compared to that of the 
protein level. In Mettl8 KO HCT116 cells, this unbalance between ATM mRNA level 
and protein level was most dramatic, as ATM protein level elevated drastically with 
ATM mRNA remaining almost unchanged. Thus, it is reasonable to say that the 
regulation of Mettl8 on ATM is primarily not on a transcriptional level. There was no 
significant difference of ATM protein stability observed between Mettl8 KO cells and 
control cells either (data not shown). As introduced in Chapter 1, ATM expression is 
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tightly regulated by several microRNAs. Whether these microRNAs are changed in 
our ΔSAM mutant or Mettl8 KO cells is currently under investigation. 
There is a minor upregulation of H2AX mRNA level in ΔSAM mutant or Mettl8 KO 
cells. However, H2AX mRNA upregulation was not found in Mettl8 KD or even 
Mettl8 and Mettl2 double KD cells, suggesting that there is a different mechanism 
employed in ΔSAM mutant cells, in line with a more profound change in gene 
profiling in ΔSAM mutant cells revealed by microarray study compared to Mettl8 
single KD cells. Back to the time we did microarray analysis, we didn’t know that 
only Mettl8 and Mettl2 double KD would have significant effect on ATM-p53 
pathway and we did not have Mettl8 KO cells, microarray analysis was only done in 
cells with Mettl8 single KD. Maybe double KD cells or KO cells will have more 
dramatic change in gene profiling compared to their controls. 
ATM and H2AX are important tumor suppressor genes which are colocalized on 
chromosome 11q and frequently deleted or translocated in certain tumors (Srivastava, 
Gochhait, de Boer, & Bamezai, 2009). ATM is found to be downregulated in certain 
tumor models (Bose et al., 2007; Roy, Wang, Makrigiorgos, & Price, 2006; Vo et al., 
2004). Therefore, our finding could unveil another potential target for cancer therapy 
or clinical application. 
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3.3 Mettl8 regulates cell growth and survival.  
Since Mettl8 can modulate ATM-p53 pathway, we then further investigate its 
physiological significance in cell growth.  
As ATM has been shown to be essential for cell checkpoint response, we analyzed the 
cell cycle profiles of those HCT116 stable clones with Mettl8 wt or ΔSAM mutant 
overexpressed. As shown in Figure 20C, wild-type Mettl8 cells showed similar 
profile as empty vector cells at unstimulated condition, while ΔSAM mutant cells 
showed slightly more accumulation of G2/M population. This trend was more 
dramatic in the irradiation condition, all three cell lines showed accumulated G2/M 
cells 24h after 10 Gy gamma irradiation, among which ΔSAM mutant cells showed a 
significantly highest percentage of G2/M cells. This arrest could be due to 
upregulated p21 (Figure 16A and Figure 20F) as an established mechanism to prevent 
damaged cells from migrating into mitosis. However, no significant difference was 
observed in MTS cell proliferation assay (Figure 20. Mettl8 is a regulator of cell 
growth. or colony formation assay (Figure 20. Mettl8 is a regulator of cell growth. 
between HCT116 stable cells with empty vector, wt or ΔSAM mutant Mettl8. Results 
of these two assays indicate that the overall growth and survival ability was not 
affected by overexpression of wt or ΔSAM mutant Mettl8. 
The idea of studying the survival and proliferation ability of cells in soft agar was 
first developed by Hamburger and Salmon in 1977 (Hamburger & Salmon, 1977). 
The more cancerous cells are the stronger ability they have to grow in 
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anchorage-independent condition. In the current study, the overexpression of wt or 
ΔSAM mutant Mettl8 in HCT116 colon cancer cells was assessed in soft agar assay 
to elucidate its effect on the cells’ anchorage-independent growth ability. ΔSAM 
mutant Mettl8 cells showed much reduced colony number compared to empty vector 
and wildtype Mettl8 cells (Figure 20D&E), which suggests that overexpression of 
ΔSAM mutant Mettl8 in cells leads to an attenuated ability in anchorage-independent 
growth.  
Although there is minor upregulation of p21 mRNA in ΔSAM mutant cells, there is 
no upregulation of Puma, the gene responsible for p53 mediated apoptosis in this 
situation, especially in the irradiation, suggesting a specific selection of p53 target 
genes for ΔSAM mutant cells (Figure 20F) which showed different pattern compared 
to Mettl8 and Mettl2 DKD (Figure 20F). In the DKD cells, there was a drastic 
elevation of both p21 and Puma mRNA expression even in untreated cells. Consistent 
with the qPCR result, cell growth and viability were greatly compromised in Mettl8 
and Mettl2 DKD cells compared to scramble control cells. If kept in culture for 
longer time, the survived ‘DKD’ cells under puromycin selection would finally lose 
Mettl8 or Mettl2 KD and become single KD cells, indicating that Mettl8 and Mettl2 
DKD is lethal to the cells. However, in the Mettl8 KO cells, there was a lower 
induction fold of both p21 and Puma upon irradiation compared to control cells 
(Figure 20G), although p53 S15 activation was much higher (Figure 18C). In line 
with this unusual qPCR result, Mettl8 KO HCT116 cells actually grew faster than 
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control cells in colony formation assay as shown in Figure 20H, which is in dramatic 
contrast with the scenarios in ΔSAM mutant cells and DKD cells,.  
To try to explain the reduced growth ability of HCT116 ΔSAM mutant cells in soft 
agar assay, we tested the mRNA level of E-cadherin (CDH1) in the cells. CDH1 is a 
tumor suppressor as loss of it can lead to cancer cell invasion and tumor metastasis 
(van Roy & Berx, 2008); it was shown in several cancers including colon cancer (X. 
Chen et al., 2012). A shown in Figure 20I, ΔSAM mutant cells had almost 3-fold 
increase of CDH1 mRNA level compared to Mettl8 wt cells, which is in line with soft 
agar result. In great contrast, Mettl8 KO cells had over 60% decrease of CDH1 
mRNA compared to control cells. 
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Figure 20. Mettl8 is a regulator of cell growth. 
A) Growth of HCT116 stable cells with Mettl8 variants was measured using Promega 
CellTiter 96® AQueous Non-Radioactive Cell Proliferation Assay. The experiment 
was done three times independently. 
B) Quantification of colony formation assay. The colony number shown is average 
of three independent experiments. HCT116 stable cells with Mettl8 WT or SAM 
overexpressed were seeded at 500 cells/well in 6-well plates in triplicate manner. 
After 14 days colonies were stained and scanned in Bio-Rad Gel Doc EZ system. 
Colonies with more than 50 cells were counted with Quantity One software. 
C) HCT116 stable cells with Mettl8 variants were stained with propidium iodide (PI) 
and profiled for cell cycle by FACS. The experiment was done three times 
independently. Data was analyzed with FlowJo software.  
D) HCT116 stable cells with Mettl8 WT or SAM overexpressed were seeded at 
2500 cells/well in 6-well plates in triplicate manner. After 20 days colonies grown 
in soft agar were stained and scanned in Bio-Rad Gel Doc EZ system. Colonies 
with more than 50 cells were counted with Quantity One software. The picture is 
representative of three independent experiments.  
E) Quantification of soft agar assay. The colony number shown is average of three 
independent experiments. * indicates p<0.05 by single-tail t-test analysis. 
F) HCT116 stable clones with Mettl8 variants were irradiated at 10Gy and left in 
recovery for 24h (upper panel). HCT116 cells were infected with lentiviruses 
harboring shRNA(s) against Mettl8 (M8), Mettl2 (M2), both Mettl8 and Mettl2 
(M8+2), or scramble control for 72 hours (lower panel). RNA was extracted and 
reversed for qPCR analysis with indicated primers. 
G) HCT116 cells with Mettl8 KO or control were irradiated at 10Gy and left in 
recovery for 24h. RNA was extracted and reversed for qPCR analysis with indicated 
primers. 
H) HCT116 cells with Mettl8 KO or control were seeded at 500 cells/well in 6-well 
plates in triplicate manner. After 14 days colonies grown were stained by crystal 
violet and scanned in Bio-Rad Gel Doc EZ system. The picture is representative of 
three independent experiments. 
I) RNA was extracted from HCT116 stable cells with Mettl8 wt or SAM, and 
HCT116 cells with Mettl8 KO or control. Then the samples were reversed for 
qPCR analysis with CDH1 primer.
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3.3.1 Discussion 
In this chapter, the effect of ΔSAM mutant overexpression, Mettl8&Mettl2 DKD or 
Mettl8 KO on cell growth and survival was assessed in HCT116 cells. 
Our observation of G2/M arrest in HCT116 cells 24h after irradiation is consistent 
with previous reports (Essmann et al., 2005; Flatmark et al., 2006). The significant 
higher accumulation of G2/M cells in ΔSAM mutant cells correlates with the 
hyperactivation of p21 in the same cells, as p21 is an essential gene in cell cycle 
arrest after DNA damage. p21 overexpression can lead to G1, G2 or S arrest in 
different circumstances (Gartel & Tyner, 2002) and it is required to sustain G2/M 
arrest after DNA damage (Bunz et al., 1998; Lossaint, Besnard, Fisher, Piette, & 
Dulic, 2011; Wendt et al., 2006). 
The tumor suppressor p53 is a highly potent transcription factor maintained at low 
levels under normal circumstances. In response to cellular stress such as DNA 
damage p53 gets stabilized and activated, the biological outcome of which can be 
growth arrest, apoptosis and other responses (Vogelstein, Lane, & Levine, 2000). The 
choice between growth arrest and apoptosis is dependent on a complex range of 
factors including cell type, stress type, the presence of p53 co-activators and 
regulators and post-translational modification of p53 (Meek, 2004; Vousden, 2006). 
The existence of Mettl8 seems to be crucial for p53 regulation of certain downstream 
targets as Mettl8 KO in cells resulted in a suppressed induction of p21 and Puma even 
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with higher level of activated p53 present upon IR treatment (Figure 18C&D, Figure 
20G). 
Epithelial-mesenchymal transition (EMT) is a key biological process involved in 
development, cancer invasion and metastasis. Although loss of E-cadherin (CDH1) 
expression is not causal or necessary in EMT (Hollestelle et al., 2013), CDH1 
expression is closely associated with EMT and cancer metastasis (Cano et al., 2000; 
Kalluri & Weinberg, 2009; Onder et al., 2008). We demonstrated that Mettl8 could 
affect CDH1 level in cells although the underlying mechanism is unknown yet; this 
implies a possible role of Mettl8 in cancer metastasis and embryonic development. 
ATM total level and activation upregulation were consistently observed in ΔSAM 
mutant cells, DKD cells, and Mettl8 KO HCT116 cells, but the overall output effects 
on cell growth and survival differ so much (Figure 21). This suggests a role of Mettl8 
in other unknown pathways that play a more dominant role in regulating cell growth 
than ATM-p53 DDR, which requires further investigation.
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Figure 21. Mettl8 and ATM. 
A diagram summary of the experiment results in Chapter 3.2&3.3.  
The effect of Mettl8 expression level change on Mettl2 expression was not studied. So Mettl2 
protein level was depicted as unchanged in the figure except in the DKD cells. The protein 
localization was not taken into consideration. 
Chapter 4 Conclusions, Discussions and Future Work  
109 
Chapter 4 Conclusions, Discussions and Future Work 
Generally we have fulfilled the aim of our research and elucidated some important 
functions of human Mettl8 protein especially in DDR. 
4.1 Mettl8 is novel substrate of ATM and regulates ATM expression 
and activation. 
In a large scale ATM substrates study from Elledge group (Matsuoka et al., 2007), 
about 700 proteins with pS/TQ motif were identified in pS/TQ IP followed by Mass 
spectrometry. Many novel substrates were listed in the supplementary data of their 
paper with unclear functions, expanding our understanding of ATM kinase function 
beyond DNA damage response. Among those, we found the peptide around Mettl8’s 
Ser405 site, which supports our finding of this unique pS/TQ. However, we not only 
validated this site in two cell lines but also did further mutagenesis study to confirm 
this is the only phosphorylation site by ATM in response to IR in which the role of 
ATM has been established. Our work with chemical inhibitor further consolidated this 
dependence on ATM (Figure 14B&C) and the cell fractionation work with mutants 
indicated that this phosphorylation is likely to occur in nucleus where ATM executed 
its DNA damage response function (Figure 12A&Figure 14E).  There is a concern 
about the human specific feature as this pS/TQ motif is missing in Mettl8 from other 
organisms, and only the longest isoform of human Mettl8 has this motif. Actually, this 
situation is also observed in many important mediators of DNA damage response in 
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that mouse and human homologue indeed show variance in the pS/TQ sites (Matsuoka 
et al., 2007).  
Mettl8 was not found to co-localize with IRIF as shown by H2AX foci (data not 
shown), suggesting it may indirectly affect DNA damage response. We shall bear on 
mind that not all ATM substrates are recruited to such foci; a well-known exception is 
Chk2 although it plays critical role in checkpoint response elicited by DNA damage.  
ATM gene variants and mutations were generally more appreciated and associated 
with cancer risks in previous studies (Mitui et al., 2009; Shen et al., 2012), especially 
in breast cancer (Ahmed & Rahman, 2006; Broeks et al., 2008; Khanna & 
Chenevix-Trench, 2004). However there were also reports about ATM protein level as 
a useful marker for identifying breast cancer patients at high risk of clinical 
radiosensitivity (Fang et al., 2010) and the important role of ATM protein level in the 
maintenance of the shortened telomeres commonly found in prostate cancer cells 
(Angèle et al., 2004). Our result about Mettl8 and ATM level suggested that loss of 
Mettl8 protein expression could be a possible reason for increased ATM level in 
cancer cells. 
4.2 Mettl8 is a potential methyltransferase with unknown substrate. 
The most conserved feature of Mettl8 is SANT and SAM domain. Mettl8 is named 
after its SAM binding domain, which suggests it could be a class I SAM dependent 
methyltransferase. However, it’s challenging to identify the exact substrate for any 
methyltransferase given its diverse candidate atoms to accept methyl group which 
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could be on DNA, protein or small molecule. We can get some information from 
mutant phenotype but the final proof is still biochemical assay (T. C. Petrossian & 
Clarke, 2011). Recently Mettl2 was found to be homolog of a yeast tRNA 
methyltransferase Trm140. Whether Mettl8 could work similarly on RNA species is 
under investigation.  
In conclusion, in this study Mettl8 is identified as a novel target of Stat3 and a 
potential methyltransferase with SAM binding activity. And it is also a new substrate 
of ATM which phosphorylates Mettl8 at S405. Mettl8 mutation on SAM domain or 
Mettl8 knockout or Mettl8 and Mettl2 double knockdown can promote ATM 
activation possibly via upregulation of ATM expression level. Hyperactivation of 
ATM after irradiation in turn phosphorylates p53 and H2AX to initiate DNA damage 
response. The role of Mettl8 in DNA damage response is established at least in two 
parts: it is a substrate of ATM and in some unknown manner it regulates ATM level and 
activation in DSB.  
To our knowledge, our work is the first detailed study of one potential 
methyltransferase as an ATM substrate and its modulating effect on ATM expression 
and activation. Interestingly several other methyltransferase proteins were listed in 
the Elledge group’s ATM/ATR substrate list (Matsuoka et al., 2007): tRNA 
(adenine(58)-N(1))-methyltransferase non-catalytic subunit TRM6, histone lysine 
N-methyltransferase 2D, euchromatic histone-lysine N-methyltransferase 1 and 2 
( EHMT1&2), Mettl3, Mettl10d, and Mettl18. It will be very intriguing to study how 
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other ATM/ATR-substrate MTases interact with ATM/ATR, which is very likely to 
greatly expand our view of DDR, ATM/ATR and MTase. 
4.3 Limitations of the current work 
The first limitation of our current work is that the main results about Mettl8 and ATM 
were obtained in two cell lines: HCT116-WT and 293T. Whether this could apply to 
other cell lines like human fibroblasts or in vivo situations requires further 
investigation. Although mouse Mettl8 has no pS/TQ motif, it does have a SAM 
domain for potential methyltransferase activity, so it is also interesting to study 
Mettl8 and ATM in mouse. 
Another limitation is the potential off-target effect of the CRISPR/Cas9 knockout, as 
CRISPR RNA-guided nuclease was reported to be highly active even with 
imperfectly matched RNA-DNA interfaces in human cells (Fu et al., 2013). More 
gRNAs should be tested and rescue experiment can provide extra evidence. 
We established Mettl8 as a Stat3 target but we did not do further in-depth studies to 
find a physiological role for this link. There were reports about Stat3 modulating the 
DDR pathway (Barry et al., 2010) and involvement of ATM in Stat3 phosphorylation 
(Y. Zhang et al., 2003), whether Mettl8 plays a role in these regulations is also worth 
studies. 
4.4 Future work  
Much remains to be done in order to achieve a full understanding of the mechanism 
underlying the regulation of Mettl8 on ATM expression and activation and the role of 
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Mettl8 in other pathways. In order to deepen and broaden our knowledge of Mettl8 
and ATM, it is imperative to investigate the following:  
i. The miRNA profile of Mettl8 ΔSAM mutant cells and Mettl8 KO cells 
compared to their respective control. 
As mentioned earlier, the regulation of Mettl8 on ATM expression is not mainly 
on a transcription level or by protein stability regulation. Since there are many 
miRNAs reported to regulate ATM expression, it is reasonable to test whether 
ATM regulating miRNAs are changed in Mettl8 ΔSAM mutant cells and Mettl8 
KO cells. 
ii. The effect on ATM pathway of Mettl8 with mutation of SANT or NRB domain. 
Besides SAM domain, SANT and NRB domain also execute important functions 
in Mettl8 protein as shown by the Schuger group (Badri et al., 2008; Jakkaraju et 
al., 2005). Studying whether disruption of these domains would affect ATM 
expression or activation is essential for a full understanding of Mettl8’s 
regulation of ATM. 
iii. The whole protein and mRNA profile change in Mettl8 KO cells compared to 
control. 
A view of the global mRNA and protein change induced by Mettl8 KO may help 
explain the distinct effect of ΔSAM mutant and Mettl8 KO on cell growth, and 
also provide insights into the function of Mettl8 in other pathways. 
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iv. The role of Mettl8 in other ATM related functions besides DDR. 
v. The relevance of the nucleolar localization of Mettl8 to cell stress response and 
function of p53. 
Nucleolus is more and more appreciated as a central hub in stress response that 
coordinates cell growth arrest and DNA repair mechanisms (Antoniali, Lirussi, 
Poletto, & Tell, 2013; Boulon, Westman, Hutten, Boisvert, & Lamond, 2010), 
and also a stress sensor responsible for p53 level maintenance (Rubbi & Milner, 
2003). Given the preferred localization of Mettl8 in nucleolus, its potential 
enzymatic function as RNA methyltransferase and the regulation of ATM we 
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